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MicroRNA 1207-3p in Prostate Cancer 
by 
Dibash K. Das 
 
Advisor: Dr. Olorunseun O. Ogunwobi 
 
Prostate cancer (PCa) is the most commonly diagnosed male cancer and the second leading cause 
of cancer-related death for men in the United States. Understanding the molecular mechanisms 
involved in progression from the asymptomatic androgen-dependent PCa to the lethal castration 
resistant prostate cancer (CRPC) is a major challenge. MicroRNAs (miRNAs), are known to be 
dysregulated in PCa. MicroRNA-1207-3p (miR-1207-3p) is encoded by the non-protein coding 
gene locus PVT1 on the 8q24 human chromosomal region, an established PCa susceptibility locus. 
However, the role of miR-1207-3p in PCa is unclear. We have discovered that miR-1207-3p is 
significantly underexpressed in PCa cell lines compared to normal prostate epithelial cells. 
Moreover, the increased expression of miR-1207-3p in PCa cells significantly inhibits 
proliferation, migration, and induces apoptosis via direct molecular targeting of Fibronectin type 
III domain containing 1 (FNDC1) and consequent loss of expression of fibronectin (FN1), and 
consequent loss of expression of the androgen receptor (AR). PCa cell lines and patient-derived 
tissues revealed significant overexpression of FNDC1, FN1 and AR which are factors that 
positively correlate with aggressive PCa. Also, metastatic PCa displayed concurrent 
overexpression of FNDC1, FN1 and AR. Taken together, this is the first description of a novel 
miR-1207-3p/FNDC1/FN1/AR regulatory pathway in PCa.  For the unbiased discovery of the 
molecular targets of miR-1207-3p, we designed and synthesized a novel synthetic biotinylated 
v 
 
miR-1207-3p duplex (NB1207), and a novel synthetic biotinylated scramble duplex (NB1). We 
observed that NB1207, but not the scrambled duplex NB1, directly targets the 3’UTR of FNDC1 
and more effectively inhibits proliferation, inhibits migration and increases apoptosis of PCa cells 
including those aggressively tumorigenic. Interestingly, the location of miR-1207-3p on the 8q24 
human chromosomal region is downstream of the proto-oncogene, c-MYC. c-MYC has been 
linked to castration resistant prostate cancer (CRPC). However, the mechanisms regulating c-MYC 
remain unclear in CRPC. In this study, we discovered that c-MYC is regulated and therapeutically 
targetable via the miR-1207-3p/FNDC1/FN1/AR pathway in CRPC. miR-1207-3p negatively 
correlates with c-MYC in prostate tumors with Gleason score ≥8. Additionally, we discovered that 
overexpression of miR-1207-3p significantly inhibited proliferation and increased apoptosis in 
CRPC cells. We also compared the efficacy of NB1207 and NB5, two novel synthetic analogs of 
miR-1207-3p, with the currently used therapies against CPRC: abiraterone, enzalutamide, and 
apalutamide (phase 3 clinical trial). Treatment with NB1207 and NB5 resulted in increased 
inhibition of AR-V7 protein expression, and more significant inhibition of proliferation and 
increases in apoptosis of CRPC cells compared to abiraterone, enzalutamide and apalutamide. 
These results demonstrate that synthetic analogs of miR-1207-3p, such as NB5 and NB1207, may 
be a novel strategy for successful therapeutic targeting of c-MYC via the miR-1207-
3p/FNDC1/FN1/AR pathway in CRPC.  In summary, the present study indicates that miR-1207-
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Prostate cancer (PCa) is the most commonly diagnosed cancer among males in the western world1-
3. Accounting for 180,890 new cases in the US in 2016, PCa is a major cause of cancer morbidity 
and mortality 4-6,7. The annual morbidity grows as the rate of PCa has increased by 14% over the 
last two decades3,6,8,9. One of the challenges faced in combating PCa is its considerable 
heterogeneity1,9,10. Typically, early PCa is asymptomatic, and advanced PCA is associated with 
the appearance of symptoms such as blood in the urine, burning/pain during urination and 
metastasis to the bones11-13. Active research continues in the areas of early detection and treatment 
of PCa, but these efforts have met obstacles. The current screening tool for PCa, prostate specific 
antigen (PSA), is highly controversial as it is not PCa-specific and has a high false positive rate14,15. 
This poor correlation leads to adverse consequences associated with unnecessary diagnosis and 
overtreatment of non-aggressive PCa14-16. Unfortunately, treatments are highly aggressive, 
invasive, costly and may impact a man’s long-term quality of life due to complications or severe 
side effects12,17,18.   
 
Effective methods for early detection of clinically relevant PCa are crucial and should minimize 
unnecessary, aggressive treatments and cancer-related deaths. Currently, there are no satisfactory 
biomarkers available that are both effective for the early detection of PCa and sensitive enough to 
discriminate between indolent and aggressive PCa1,13,19. Understanding the molecular mechanisms 
underlying the development of PCa is necessary for the discovery of novel and efficacious 





The role of AR and AR-V7 in prostate cancer 
The Androgen hormone stimulates and controls the development and maintenance of male 
characteristics by binding to AR20,21. The AR, a member of the steroid hormone receptor 
superfamily, contains 8 canonical exons encoded in four functional domains17,22,23. The domains 
include the NH2-terminal transactivation domain (NTD), the DNA-binding domain (DBD), the 
hinge region, and the ligand-binding domain (LBD)17,22,23. The AR carries out its cellular functions 
as a ligand-activated transcription factor17,22,23. However, PCa is an androgen-driven disease and 
the androgen receptor (AR) plays a critical role in the development and progression of PCa17,20,21. 
PCa typically starts as androgen-dependent and most men are responsive to medical and surgical 
androgen deprivation therapies (ADT)12,17,21,24,25. However, in spite of these efforts, the cancer 
inevitably reoccurs in up to 30% of men, who progress to androgen-independent PCa also known 
as castration-resistant PCa (CRPC)6,12,17,21. It is this highly aggressive form of PCa that is 
lethal17,21,24.  
 
The therapeutic options for advanced PCa are limited, and minimally effective 12,26,27. Current 
CRPC anti-androgen therapies such as abiraterone, enzalutamide and apalutamide have focused 
on the androgen-dependent activation of AR through its ligand-binding domain (LBD)20,22,28.  
Unfortunately, several studies have shown that androgen receptor variants (AR-Vs) which lack the 
LBD are resistant to these LBD-targeting AR antagonists or agents that repress androgen 
biosynthesis22,28-30. AR-V7 is the most abundant and the most studied member because it is the 
only known variant of which the encoded endogenous protein is detectable in clinical 
specimens22,28,30,31. AR-V7 contains the first three canonical exons of the AR, however AR-V7 is 
followed by variant-specific cryptic exon 3 (CE3) within intron 3 which prematurely truncates the 
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AR in a manner that deletes exons 4-828,30,32. These deleted exons normally code for the hinge 
region and LBD29-31. Consequently, AR-V7 remains constitutively active as a transcription factor, 
independent of androgen signaling28-30. Furthermore, studies have shown that the detection of AR-
V7 in PCa has been correlated with CRPC and resistance against enzalutamide and 
abiraterone22,28,30. Consequently, although the mechanism is not fully understood, the androgen 
receptor (AR) along with AR-V7 are considered important targets for CRPC therapy12,17,25.  
 
Role of microRNAs in cancer 
MicroRNAs (miRNAs) are small (18-22 nucleotides) non-protein coding regulatory RNAs, which 
play an essential role in post-transcriptional gene regulation27,33-35. The canonical biogenesis  
of miRNAs in vertebrate and invertebrate cells involves two key processing steps35-37. In the 
nucleus, the RNase III enzyme complex Drosha, cleaves long primary miRNA transcripts (pri 
-miRNA) containing one or more hairpin structures to yield stem-loop precursor miRNAs (pre 
-miRNA) that are approximately 55-70 nucleotides in length35-37. These pre-miRNAs are then 
exported to the cytoplasm where they are subsequently cleaved by another RNase III enzyme,  
Dicer, to remove the loop structure to produce a mature miRNA35-37.   
 
MicroRNAs are conserved, endogenously synthesized and have been shown to regulate the 
expression of nearly 60% of human genes by regulating many biological processes including 
proliferation, migration and apoptosis27,33-36,38.  Consequently, miRNAs possess great potential as 
ideal therapeutic tools for human cancers7,35,39. The canonical mechanism of miRNA targeting 
involves an interaction between the 5’ end of the miRNA called the ‘seed region’ (from nucleotides 
2 to 8) and the 3’ untranslated region (3’ UTR) of the mRNA35-37. The seed region is the most 
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conserved region of miRNAs, and in many instances a seed match alone is sufficient to confer 
mRNA recognition, which results in the suppression of protein translation35-37. In the case of 
perfect complementarity between the miRNA and the mRNA target site, the mRNA is degraded35-
37. However, because high complementarity is not required for miRNA regulation on an mRNA, a 
single miRNA can target multiple genes35-37.   
 
An abundant body of data has demonstrated that miRNA expression are found to be aberrant in 
many cancers including PCa4,34,40,41. Many miRNAs’ expression reflect the tumor of origin, 
functioning as either oncogenes or tumor suppressors according to the roles of their target genes 
which strongly supports their use as therapeutic tools for cancer management33,40,42.  Since miRNA 
expression profiles may serve as “unique signature” in classifying human cancers, they have 
potential to be used for effective early detection and prognostic biomarkers in PCa as well8,34,43,44.  
Several recently discovered miRNAs based on serum, tumor, blood, urine and tissue-derived 
samples obtained from human patients from various cancers have demonstrated the stability and 
robustness of miRNAs to serve as clinical biomarkers7,8,34,43,45,46. A biomarker that reliably 
discriminates/distinguishes indolent from aggressive PCa is useful for treatment stratification. 
Aggressive treatment may be initiated early in rapidly lethal PCa while unnecessary for otherwise 
indolent PCa. Furthermore, it raises the potential for successful miRNA based therapy.  Ultimately, 
few reports describe the role of miRNAs in PCa aggressiveness, highlighting the need for 






The role of miRNA-1207-3p in prostate cancer 
It is now well-known that the 8q24 human chromosomal locus has profound genomic instability 
in PCa2,47-50. Several studies, including one published recently from our lab, have shown that the 
300kb long non-protein coding gene locus, PVT1, located on the 8q24 chromosomal locus, is 
dysregulated in PCa47.  PVT1 has at least 12 different exons and encodes six microRNAs, 
including microRNA-1207-3p (miR-1207-3p)1,47,50,51.   
 
Five of the six miRNAs are not associated with annotated PVT1 exons, rather they are intronic, 
including miR-1207-3p1,47.  However, no study has been performed on the status and biological 
functions of miR-1207-3p in PCa to date. Our study is the first to determine the role of miR-1207-
3p in PCa1. To explore the molecular mechanisms through which miR-1207-3p exerts its PCa, the 
molecular targets of miR-1207-3p must be identified. No studies have ever shed light on the direct 
molecular targets of miR-1207-3p in any system. To investigate this, synthetic biotinylated analogs 
of miR-1207-3p were designed and synthesized1.   
 
FNDC1 and FN1 regulation by the miR-1207-3p pathway in prostate cancer 
We identified Fibronectin type III domain containing 1 (FNDC1) as a putative molecular target 
of miR-1207-3p. FNDCI contains the conserved ‘Fibronectin type III domain’ of Fibronectin 
(FN1)52-55. FN1 is a glycoprotein consisting of three domains56-58. These FN1 domains (type I, 
type II and type III), have undergone exon shuffling resulting in their abundance in other 
molecules54,59,60. FN1 has been implicated in carcinogenesis and known to be a regulator of cell 
migration, proliferation and apoptosis61-64. So far, only two miRNAs have been shown to directly 
target a member of the FN1 family in PCa, miRs-143 and-145, which are both downregulated in 
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PCa cell lines and tissues65,66. However, these studies did not reach a consensus on their effects 
on FN134,65,67 
 
The biological function of FNDC1 has not been well studied. The FNDC1 gene is located on the 
6q25.3 human chromosomal region52,68. The limited data available on FNDC1 reports that 
FNDC1 has also been associated with prostate leiomyosarcoma 94,69. Prostate leiomyosarcoma is 
a mesenchymal tumor that is particularly rare, highly aggressive, and accounts for less than 3.7% 
of primary prostate diseases69,70.  However, a functional role for FNDC1 in PCa has not been 
reported. Our study is the first to demonstrate a microRNA regulation of FNDC1. 
 
c-MYC regulation by the miR-1207-3p pathway in prostate cancer 
Studies have shown that PVT1/MYC cooperation is a fundamental feature in all cancers with 8q24 
amplification and 98% of the 8q24 amplicons contained amplification of both the MYC and PVT1 
loci71-74. c-MYC is a proto-oncogene linked to PCa aggressiveness48,71,72,74-76. Furthermore, c-
MYC has been a consequence of antiandrogen treatment, and has been reported to be downstream 
of AR in some PCa71,74,75,77. Interestingly, miR-1207-3p is encoded at the PVT1 gene locus, which 
is located downstream of c-MYC on the 8q24 human chromosomal region48,71,72,74,78. Although 
miRNAs have also been implicated in the regulation of c-MYC, the mechanisms regulating c-
MYC remains unclear in PCa79,80. Consequently, we aimed to determine if c-MYC is regulated 
and therapeutically targetable via our novel miR-1207-3p pathway.  
 
Clinical significance of miR-1207-3p in prostate cancer 
Using our novel analogs, we sought to investigate if miR-1207-3p regulates AR as this may play 
a role in the progression from androgen-dependent to the life-threatening castration-resistant 
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prostate cancer (CPRC)5,17,34. At diagnosis, clinical and pathologic features, such as prostate 
specific antigen (PSA) level, pathologic Gleason grade, and tumor stage, are used to inform clinical 
decision-making8,9,43. The Gleason grading system is used to help evaluate the prognosis of men 
with PCa using samples from a prostate biopsy25.  To determine if miR-1207-3p can be a useful 
non-invasive biomarker in PCa clinical decision-making, we examined the expression levels of 
miR-1207-3p and its molecular targets in PCa patients by real-time quantitative reverse 
transcription polymerase chain reaction (qRT-PCR), and publicly available gene expression 
datasets in the Oncomine database. To assess miR-1207-3p’s ability to improve risk stratification 
in human clinical PCa, we analyzed correlation with Gleason scores. Additionally, because CRPC 
has been shown to be resistant to current anti-androgen therapies, preventing/treating antiandrogen 
resistance is a major clinical challenge. Therefore, we compared the efficacy of NB1207 and NB5, 
two novel synthetic analogs of miR-1207-3p, with current anti-AR treatments for CRPC 
(abiraterone, enzalutamide and apalutamide) in vitro. 
 
Racial disparity in prostate cancer 
For reasons still unclear, men of African ancestry (moAA) have the worlds’ highest incidence of 
PCa 47,81-84. MoAA exhibit 19% increased incidence and 37% increased mortality rate from PCa 
compared to Caucasian men (CM) and disparities in tumor aggressiveness remain after controlling 
for social determinants82-86. Consequently, aggressiveness of PCa may be due to specific biological 
factors83,87. To address this high mortality, effective early detection and therapeutic strategies are 
needed82,83,87,88. Undoubtedly, miRNAs are dysregulated in PCa85,89. However, miR-1207-3p 
expression in PCa in moAA is unknown. Therefore, we investigated the expression of miR-1207-
3p and its molecular targets in PCa cells of moAA by evaluating the expression profile of miR-
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1207-3p, FNDC1, FN1, AR and c-MYC in the prostate tissues in a cohort of West African Black 
males. Our study seeks to determine if miR-1207-3p and its molecular targets may be useful in 
increasing our understanding of the molecular mechanisms underlying PCa in moAA. Moreover, 
such strategies have the prospective to ultimately result in novel diagnostic, prognostic biomarkers 























































Cells and cell culture conditions 
Androgen-dependent RWPE-1 cells were cultured in Keratinocyte-Serum free medium (SFM) 
supplemented with 0.05 mg/ml bovine pituitary extract (BPE), 5 ng/ml epidermal growth factor 
(EGF) and 1% Penicillin-Streptomycin. Androgen-dependent WPE1-NA22 cells were cultured in 
Keratinocyte-SFM medium supplemented with 0.05 mg/ml BPE, 5 ng/ml EGF and 1% 
Penicillin/Streptomycin. Androgen-dependent MDA PCa 2b cells were cultured in F-12K medium 
supplemented with 20% fetal bovine serum, 25 ng/ml cholera toxin, 10 ng/ml mouse Epidermal 
Growth Factor, 0.005 mM phosphoethanolamine, 100 pg/ml hydrocortisone, 45 nM selenious acid, 
0.005 mg/ml bovine insulin. Androgen-independent PC-3 cells were cultured in F-12K medium 
supplemented with 10% Fetal Bovine Serum and 1% Penicillin/Streptomycin. Androgen-
independent 22Rv1 cells were cultured in RPMI 1640 supplemented with 10% heat inactivated 
FBS, and 1% Penicillin/Streptomycin. RWPE-1, WPE1-NA22, PC-3, MDA PCa 2b and 22RV1 
cell lines were purchased from the American Type Culture Collection. Androgen-dependent 
LNCaP cells were cultured in RPMI 1640 supplemented with 10% heat inactivated FBS, 1% 
Penicillin/Streptomycin and 10nM testosterone. Androgen-independent C4-2B cells were cultured 
in DMEM supplemented with 200ml Ham’s F12, 10% heat-inactivated FBS, 1% 
Penicillin/Streptomycin, insulin (5µg/ml), triiodothyronine (13.65 pg/ml), human apo-transferrin 
(4.4 µg/ml), d-Biotin (0.244 µg/ml), and Adenine (12.5 µg/ml). The C4-2B cell line was obtained 
from MD Anderson Cancer Center under a materials transfer agreement with Hunter College of 
The City University of New York. Androgen-independent E006AA and E006AA-hT were 
cultured in DMEM supplemented with 1% fetal bovine serum and 1% Penicillin/Streptomycin. 
E006AA and E006AA-hT were obtained from Dr. Shahriar Koochekpour under a materials 
transfer agreement between Roswell Park Cancer Institute and Hunter College of The City 
12 
 
University of New York1. These cells were cultured at 37C/5% CO2, under humidified 
atmosphere. 
 
Transfection of oligonucleotide inhibitor and mimic of miR-1207-3p 
Cells were seeded in 6-well plates. After reaching 60% - 70% confluence, media is replaced with 
Opti-MEM (Thermo Fisher Scientific Inc; Wilmington, DE, U.S.A) and cells are transfected with 
either a 50nM non-targeting negative control oligonucleotide (MISSION® Synthetic microRNA 
Negative Control, product# NCSTUD001), 50nM miR-1207-3p oligonucleotide mimic 
(MISSION® microRNA Mimic, product# HMI0066), 50nM miR-1207-3p oligonucleotide 
inhibitor (MISSION® Synthetic microRNA Inhibitor, human, product# HSTUD0066) (Sigma-
Aldrich, St. Louis, MO, USA), or novel synthetic miRNA-1207-3p duplexes (biotinylated 
scramble duplex (NB1), scramble duplex (NB2), biotinylated mutant duplex (NB3), mutant duplex 
(NB4), miR-1207-3p duplex (NB5), or biotinylated miR-1207-3p duplex (NB1207), (patent 
pending)), using Lipofectamine RNAiMAX (Thermo Fisher Scientific Inc; Wilmington, DE, 
U.S.A) according to the manufacturer’s instructions. Transfected cells are then incubated at 37°C 
for a total duration of 24 hours before cells are lysated1. 
 
Transfection of siRNA 
Cells were transfected with fibronectin, FNDC1, AR or c-MYC siRNAs. Negative control 
(scramble) siRNAs which does not lead to specific degradation of any known mRNA was used as 





RNA isolation and quantitative real-time polymerase chain reaction (qPCR) analysis 
RNA isolation and qPCR were performed as previously described 90. miR-1207-3p and 
RNU6_B12 snRNA primers were purchased from (Qiagen, Hilden, Germany). Primers for human 
fibronectin mRNA, and, human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA 
were custom-designed using OligoPerfect™ Designer (Thermo Fisher Scientific Inc; Wilmington, 
DE, U.S.A)1 and purchased through Millipore Sigma (St Louis, U.S.A). 
 
Click-iT EdU Alexa Fluor 488 Imaging Kit 
Cells were transfected with either oligonucleotides of miR-1207-3p, negative controls, siRNAs 
against FNCD1, FN1, AR or c-MYC as well as synthetic analogs and mutants of miR-1207-3p. 
Assay was performed according to manufacturer’s instructions: (Click-iT™ EdU Alexa Fluor™ 
488 Imaging Kit, Cat. No.: C10337, ThermoFisher Scientific Inc; Wilmington, DE, U.S.A). EdU 
is a nucleoside analog of thymidine and is incorporated into DNA during active DNA synthesis. 
Detection is based on a click reaction, 2-3 a copper-catalyzed covalent reaction between an azide 
and an alkyne. EdU contains the alkyne and Alexa Fluor dye contains the azide.  Cells were imaged 
and analyzed using the Motic Images Plus 2.0 Software (Motic; British Columbia, Canada) and 
positive EdU signal is indicative of S-phase cell population1. 
 
Annexin V Assay 
Cells were transfected with either oligonucleotides of miR-1207-3p, negative controls, siRNAs 
against FNCD1, FN1, AR or c-MYC as well as synthetic analogs and mutants of miR-1207-3p for 
24 hours prior to Annexin V staining. Assay was performed according to manufacturer’s 
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instructions: (ApoScreen® Annexin V Apoptosis Kit-FITC, Cat. No. 10010-02, SouthernBiotech 
Birmingham, U.S.A). Annexin V and PI staining were analyzed using flow cytometry1.  
 
Luciferase reporter assay 
Human FNDC1 and miRNA target clone control vector for pEZX-MT06 were purchased from 
GeneCopoeia, Inc, Rockville, MD, USA. Cells were seeded co-transfected with luciferase-
expressing 3’ UTR clones of FNDC1 along with a 50nM miR-1207-3p oligonucleotide mimic. As 
the control, cells were also co-transfected with 3’UTR clones of FNDC1 with miR-1207-3p 
synthetic non-targeting oligonucleotide negative control. The lysate was analyzed by SpectraMax 
i3x multi-mode detection platform1.  
 
Western blot analysis 
Western blotting was performed as previously described91. Primary antibodies used were against  
human fibronectin: ab2413 (Abcam plc, Cambridge, UK), human FNDC1 (Y-12): sc-107546 
(Santa Cruz Biotechnology, TX, U.S.A), human AR: sc-7305 (Santa Cruz Biotechnology, TX, 
U.S.A), human c-MYC: ab32072 (Abcam plc, Cambridge, UK), human AR-V7-specific: 
ab198394 (Abcam plc, Cambridge, UK), human GAPDH: g9545 and beta-actin: a5441 (Sigma-
Aldrich, St. Louis, MO, U.S.A). Secondary antibodies used were either against mouse or rabbit 
(Sigma-Aldrich, St. Louis, MO, U.S.A) or goat (Santa Cruz Biotechnology, TX, U.S.A), as 
appropriate. In some cases, LI-COR with infrared fluorescence, IRDye secondary antibodies and 
LI-COR Odyssey CLx imaging system were also used to detect western blots without film or 
chemiluminescent substrates. Western blots were analyzed and quantified using Odyssey CLx 
imaging system, Image Studio version 51. 
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RNA pulldown assay 
RNA pulldown assay was performed with modifications of the protocol described by Wani et 
al92. Cells were seeded in 10 cm plates. Cells were transfected with either 1nM synthetic 
biotinylated scramble duplex (patent pending), or 1nM synthetic biotinylated miR-1207-3p 
duplex (patent pending) using Lipofectamine RNAiMAX (Thermo Fisher Scientific Inc; 
Wilmington, DE, U.S.A) for 24 hours, then lysed, according to the manufacturer’s instructions.  
Beads were washed, blocked and prepared as described92. Target mRNA was captured and post-
capture bead washing was performed. Next, target mRNA and control lysate RNA were purified 
using Qiagen RNeasy kit (Cat no: 74104, Qiagen, Hilden, Germany) according to manufacturer’s 
RNA clean-up protocol. The target mRNA and the control lysate were then quantified by 
Nanodrop 1000 spectrophotometer. For the identification of direct targets of the mature miRNA, 
using the synthetic biotinylated miR-1207-3p duplex, samples were analyzed by qRT-PCR to 
examine the mRNA expression levels and enrichment of FNDC1 and c-MYC1. 
 
Patients and Samples 
For the human study at Moffitt Cancer Center, prostate cancer tissues were collected from 377 
primary prostate cancers with macro-dissection (Table 3.1). Total RNA of tumor tissues was 
extracted and RNA samples from the 377 patient cases were analyzed by qRT-PCR to examine 
the mRNA expression levels of fibronectin. Ct-values were determined using the SDS ver2.3 
software (Bio-Rad). Fibronectin expression was normalized with GAPDH expression within each 
sample. Relative quantification of target gene expression was evaluated using the comparative 
2ΔΔCtmethod. The following primers were used: Fibronectin-F: TCG AGG AGG AAA TTC CAA 
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TG; Fibronectin-R: ACA CAC GTG CAC CTC ATC AT; GAPDH-F: ACC ACA GTC CAT GCC 
ATC AC; GAPDH-R: TCC ACC ACC CTG TTG CTG TA. 
 
To evaluate miR-1207-3p expression in clinical samples, we used tissue specimens from 404 
patients (389 CM, and 15 moAA) with primary adenocarcinoma of the prostate from 1988 to 2003 
at the Moffitt Cancer Center, Tampa, Florida, USA. After histopathologic confirmation, PCa 
tissues were obtained from unstained slides with macro-dissection. Total RNA was extracted from 
PCa tissues using superscript IV first-strand Synthesis system (Life technologies No. 18091200) 
and quantified using UV spectrophotometer NanoDrop 2000 (Thermo Scientific, USA). The 
cDNA templates were synthesized from RNA samples by SuperScript using random hexamers. 
RNA samples from the 404 patient samples were analyzed by qRT-PCR to examine the expression 
of miR-1207-3p.  
 
Gene expression was determined using power SYBR Green Real time PCR Master Mix (Life 
technologies No. 4367649) and 2.0 μl of cDNA template. qRT-PCR was performed on a ABI7900 
machine using the following amplification conditions: 10 min at 95°C; followed by 45 cycles of 
15 seconds at 95°C; 30 seconds at 55°C; and 30 seconds at 72°C. All assays were carried out in 
triplicate to control for technical variance. Ct values were determined using the SDS ver2.3 
software (Bio-Rad). miR 1207-3p expression was normalized with RNUB6_12 expressions within 
each sample. Relative quantification of target gene expression was evaluated using the 




Institutional Review Board approvals were obtained for the study protocol at the University of 
South Florida and the Moffitt Cancer Center, Tampa, Florida (Tables 3.1 & 3.2).  Signed informed 
consent was obtained from all study participants. Clinicopathological and demographic 
information of the patients are summarized in Table 3.1 and Table 3.21,2,93. 
 
In a separate study, we evaluated the expression profile of miR-1207-3p, FNDC1, FN1, AR and 
c-MYC in histologically confirmed normal prostate tissue (n=24), benign prostate tissue (n=44) 
and malignant prostate tissue (n=29) from prostatectomy or transrectal ultrasound-guided biopsies 
in patients recruited at the University College Hospital, Ibadan, Nigeria. Analysis of miR-1207-
3p, FNDC1, FN1, AR, and c-MYC expression in malignant prostate tissue with Gleason scores ≥8 
versus Gleason scores <8 was performed. This study was performed following protocols approved 
by both City University of New York Institutional Review Board and the University of Ibadan 
Institutional Ethics Board. RNA extraction, cDNA synthesis and qRT-PCR were performed to 
analyze mRNA expression of miR-1207-3p, FNDC1, FN1, AR and c-MYC. 
 
Statistical Analysis 
Differences in two and three clinical outcome groups were compared using the two-tailed 
Student’s t-test and ANOVA test, respectively. For evaluating the association of miR-1207-3p 
expression with PCa death and PCa recurrence in CM, a competing risk approach was applied. 
miR-1207-3p expression was categorized to three groups: low (<3), median (3-6) and high (≥6) 
based on the tertile cut-points. Factors associated with PCa death were evaluated using competing-
risk regression 94. The cumulative incidence curves of PCa death were generated by the subgroups 
of miR-1207-3p expression. For evaluating miR-1207-3p expression associated with PCa survival, 
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PCa death was the primary interest and non-PCa death was treated as a competing risk. Survival 
time was defined as the time from date of PCa diagnosis to date of death. For evaluating association 
of miR-1207-3p expression with PCa recurrence, PCa recurrence was the primary interest and non-
recurrence death was treated as a competing risk. Time to event was defined as time from the date 
of PCa diagnosis to PCa recurrence or non-recurrence death, whichever comes first. Data were 
censored at the last follow-up date. The same approach was applied to evaluate the association of 
miR-1207-3p expression with PCa recurrence. The candidate factors taken into consideration in 
modeling included age at diagnosis, Gleason score, and tumor stage. PSA was excluded from the 
models because the PSA values were missing in 150 CM. The level of significance was established 
using a P value less than 0.052.  
 
For functional experiments (proliferation, migration and apoptosis), results were collected from at 
least three independent experiments. All results are presented as mean ± standard error of the mean 
(SEM). Unless otherwise indicated, analysis of statistical significance of differences between 
groups was performed using two-tailed Student’s t-test, and only values with P < 0.05 were 
deemed significant. For comparison of variables, a student’s t test or analysis of variance 
(ANOVA) test or Tukey post-hoc test were used for analysis of each set of continuous and 
categorical data. Statistical differences in the relative miRNA expression profiles were determined 
with one-way, two-way analysis of variance (ANOVA) and Tukey post-hoc test using the SPSS 
Statistics software (http://www-01.ibm.com/software/analytics/spss/) on normalized data. P values 


















Chapter 3:  

















PCa is a multi-factorial, complex disease, with the exact mechanisms for its development and 
progression unclear10,12,95,96. Understanding the molecular mechanisms underlying the 
development and progression of PCa is necessary. This will aid in the discovery of novel and 
efficacious biomarkers with applications in early PCa detection and molecular therapeutic 
targeting.  
 
Genome-wide association studies (GWAS) have identified the 8q24 human chromosomal region 
as one of the most important susceptibility loci for PCa13,48,51,86,97,98. Recent studies demonstrated 
that PVT1, which is a 300kb long non-protein coding gene locus found at the 8q24 human 
chromosomal region, is dysregulated in PCa51,97,99-101. The PVT1 gene locus encodes a cluster of 
six microRNAs (miRNAs), including microRNA-1207-3p (miR-1207-3p)47,50,93. No known 
biological functions for this intron-derived miR-1207-3p has been previously reported. 
 
Aberrant miRNA expression and function has potential applications in cancers7,27,41. The objective 
of this study was to determine the expression, function, and molecular mechanisms of action of 
miR-1207-3p in PCa. Our study discovered a novel role of miR-1207-3p in the regulation of 
critical cellular functions in PCa via direct targeting of fibronectin type III domain containing 1 
(FNDC1), leading to loss of fibronectin (FN1) expression and subsequent loss of androgen 
receptor (AR) expression. We also discovered that components of this novel molecular pathway, 
FNDC1, FN1, and AR are overexpressed in metastatic PCa. This discovery of a novel miR-1207-
3p-dependent regulatory mechanism in PCa reveals the possibility of clinical applications for miR-






miR-1207-3p is significantly underexpressed in PCa cells 
To investigate the expression profile, the functional role, and the molecular mechanisms of miR-
1207-3p in PCa, a panel of 8 prostate cell lines modeling different clinical characteristics of PCa 
was used because of the widely known heterogeneity of PCa1. In detail, the panel included the 
RWPE-1 (non-tumorigenic prostate epithelial cell line, Caucasian male (CM)), WPE1-NA22 
(derived from RWPE-1, indolent, androgen-dependent, CM), MDA PCa 2b (aggressive, androgen 
dependent, from a male of African ancestry (moAA)), PC-3 (aggressive, androgen-independent, 
CM), E006AA (indolent, androgen-independent, moAA), E006AA-hT (derived from E006AA, 
aggressive, androgen-independent, moAA), LNCaP (aggressive, androgen-dependent, CM) and 
C4-2B (derived from LNCaP, aggressive, androgen-independent, CM)1 (Figure 3.1A). As shown 
in figure 3.1B, miR-1207-3p expression is significantly underexpressed in all the human PCa cell 
lines in comparison to non-tumorigenic prostate epithelial cells, RWPE-1. We observed nearly 
50% less miR-1207-3p expression in androgen-dependent PCa cell lines (WPE1-NA22, MDA PCa 
2b and LNCaP). Interestingly, the expression level of miR-1207-3p was even further decreased, 
by approximately 80%, in androgen-independent cell lines (PC-3, E006AA, E006AA-hT and C4-
2B). The data suggest that miR-1207-3p underexpression may be associated with the onset and 
progression of PCa and could potentially be used as a new predictive biomarker for monitoring 
the susceptibility of development of androgen-independent PCa. 
 
To elucidate the role of miR-1207-3p expression in PCa cell function, commercially available 
synthetic oligonucleotide mimic of miR-1207-3p (miR-1207-3p mimic), a synthetic 
oligonucleotide inhibitor of miR-1207-3p (miR-1207-3p inhibitor), or a synthetic non-targeting 
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negative control oligonucleotide (negative control) were transfected into the cells using 
Lipofectamine® RNAiMAX. A dose-response experiment analyzed using qRT-PCR 
demonstrated that the miR-1207-3p inhibitor suppresses endogenous expression of miR-1207-3p 
while the miR-1207-3p mimic imitates endogenous miR-1207-3p expression; both in a dose-
dependent fashion (Figure 3.1C-E).  A 50nM concentration of the miR-1207-3p inhibitor and the 
miR-1207-3p mimic that showed maximal specific effect on miR-1207-3p expression was used to 
determine the role of miR-1207-3p in regulating proliferation, migration and apoptosis in PCa 
cells. 
 
Figure 3.1: miR-1207-3p expression is lost in prostate cancer cells, and effect of an oligonucleotide 
inhibitor and oligonucleotide mimic of miR-1207-3p on miR-1207-3p expression.  (A) Characterization 
of non-tumorigenic and tumorigenic prostate epithelial cells. List and characteristics of human prostate cell 
lines used. CM, Caucasian Male; moAA, men of African Ancestry; AR, androgen receptor. (B) Three 
separate qPCR experiments were performed. Each experiment was done in quadruplicates. The data showed 
that miR-1207-3p expression was decreased in all the tumorigenic cell lines. (C) A dose-response test of 
the effect of an oligonucleotide inhibitor of miR-1207-3p on miR-1207-3p expression was performed on 
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RWPE-1 cells.  As a control, RWPE-1 cells were treated with 50nM non-targeting negative control 
oligonucleotide. (D & E) A dose-response test of the effect of an oligonucleotide inhibitor and an 
oligonucleotide mimic of miR-1207-3p on miR-1207-3p expression was performed on WPE1-NA22 cells, 
respectively. As a control, WPE1-NA22 cells were treated with 50nM non-targeting negative control 
oligonucleotide. Dose-dependent inhibition and dose dependent overexpression of miR-1207-3p expression 
by the oligonucleotide inhibitor and mimic of miR-1207-3p was observed. Results are presented as mean ± 
standard error of the mean (SEM). Statistical differences were determined with one-way ANOVA. All the 
criterions for significance was set at P<0.05. (Originally published in Experimental Cell Research1).  
 
Overexpression of miR-1207-3p suppresses endogenous expression of fibronectin type III 
domain containing 1 (FNDC1) and fibronectin (FN1) in PCa cells 
To explore the molecular mechanisms through which miR-1207-3p exerts its inhibitory effects in 
PCa, the potential molecular targets of miR-1207-3p were investigated. The molecular targets of 
miR-1207-3p have never been studied in any system. To identify potential targets, two different 
miRNA molecular target prediction algorithm tools, miRBase and miRDB, we used. Fibronectin 
type III domain containing 1 (FNDC1) was identified as a putative molecular target of miR-1207-
3p. FNDCI contains the conserved ‘Fibronectin type III domain’ of Fibronectin (FN1)52-55. 
However, a functional role for FNDC1 in PCa has not been reported. 
 
To initially determine if there is a relationship between FNDC1 expression, FN1 expression and 
miR-1207-3p expression, we analyzed protein expression of FNDC1 in the prostate epithelial cell 
lines described in figure 3.1A. We observed that FNDC1 protein expression was consistently 
higher in all the PCa cell lines compared to the non-tumorigenic prostate cell line, RWPE-1 (Figure 
3.2A). In repeated experiments, RWPE-1 had very low FNDC1 protein expression. Further, 
overexpression of miR-1207-3p significantly inhibited the protein expression of FNDC1 by about 





miR-1207-3p directly targets FNDC1 
To confirm that FNDC1 is a direct molecular target of miR-1207-3p, we performed a dual-
luciferase reporter assay using the Luc-Pair™ Duo-Luciferase assay system to determine if miR-
1207-3p binds to the 3’ untranslated region (UTR) of the FNDC1 mRNA.  Due to the heterogeneity 
of PCa, we utilized widely used PCa cell lines that model various characteristics of PCa. Because 
of the significantly low level of endogenous expression of miR-1207-3p in the PC-3 and MDA 
PCa 2b PCa cell lines and their widespread use, we used them as cellular models for this assay. 
PC-3 and MDA PCa 2b cells were co-transfected with both the plasmid containing the sequence 
of the FNDC1 3’UTR and miR-1207-3p 50nM mimic. Cells were transfected with 3’UTR clones 
of FNDC1 with a synthetic non-targeting oligonucleotide negative control as the control. We 
observed a direct and specific interaction between exogenous miR-1207-3p and the FNDC1 
3’UTR. Overexpression of miR-1207-3p led to the suppression of activity of the luciferase reporter 
gene fused to the FNDC1 3’UTR by about 40% in PC-3 cells and about 60% in MDA PCa 2b cells 
(Figure 3.2C) compared to the cells transfected with the non-targeting 50nM oligonucleotide 
negative control.  
 
As nearly 20% of miRNA mediated repression of target mRNAs occur without the canonical base 
pairing to the seed sequence, but rather by imperfect binding to the center of miRNA sequence, 
we further confirmed and validated that miR-1207-3p directly binds to FNDC1 by performing 
RNA pulldown using a synthetic biotinylated miR-1207-3p duplex (Patent application publication 
number, US20170121711 A1)92. This approach allows for the sensitive and specific detection of 
miRNA-mRNA interactions92. MDA PCa 2b cells were transfected with either 1nM synthetic 
biotinylated miR-1207-3p duplex or 1nM synthetic biotinylated scramble duplex as a control. 
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RNA was subsequently pulled down with streptavidin coated magnetic beads. The RNA was then 
analyzed for FNDC1 expression with qRT-PCR. We observed that compared to the RNA pulled 
down by the synthetic biotinylated scramble duplex, the RNA pulled down by the synthetic 
biotinylated miR-1207-3p duplex was significantly enriched for FNDC1 by approximately 2,000-
fold (Figure 3.2D). Therefore, FNDC1 is a direct molecular target of miR-1207-3p. 
 
Figure 3.2: FNDC1 is a direct molecular target of miR-1207-3p. (A) Western blotting experiments were 
performed. FNDC1 is overexpressed in PCa cell lines when compared to the non-tumorigenic prostate 
epithelial cell line, RWPE-1. (B) Effect of overexpression of miR-1207-3p on FNDC1 in MDA PCa 2b 
cells. (C) Luc-Pair™ Duo-Luciferase Assay was used to determine if miR-1207-3p binds to the 3’-UTR of 
FNDC1. PC-3 and MDA PCa 2b cells were co-transfected with GeneCopoeia pEZX-MT06 miRNA 
reporter empty vector or FNDC1 3’UTR-containing plasmid with a 50nM non-targeting negative control 
or miR-1207-3p 50nM mimic for 24 hours. FLuc and RLuc activity were measured. Activity is normalized 
to the negative control luciferase activity set to 1.0. Bars represent SD. *P<0.05. Data show that microRNA-
1207-3p directly targets the 3’UTR of FNDC1. (D) Biotinylated microRNA pulldown was performed for 
the isolation of direct targets of a mature miRNA, using synthetic biotinylated miRNA duplexes. 
Biotinylated scramble duplex and biotinylated microRNA-1207-3p duplex were transfected into MDA PCa 
2b cells. Pull-down miRNA enrichments were assayed by qRT-PCR. Activity is normalized to the 
biotinylated scramble duplex set to 1.0. Bars represent SD. *P<0.05. (Originally published in Experimental 
Cell Research1).  
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miR-1207-3p regulates FN1 via FNDC1 
To examine the relationship between FN1 expression and miR-1207-3p, we analyzed mRNA and 
protein expression of FN1 in the previously described cell lines (Figure 3.1). The data revealed 
higher FN1 mRNA expression in all the PCa cell lines compared to non-tumorigenic RWPE-1 cell 
line1 (Figure 3.3A). Interestingly, PCa cell lines from moAA (MDA PCa 2b, E006AA and 
E006AA-hT) showed higher FN1 expression compared with cells from Caucasian men, suggesting 
that FN1 may play a role in the racial disparity in PCa (Figure 3.3A). Additional validation by 
western blotting confirmed increased FN1 protein expression in all the PCa cell lines compared to 
the non-tumorigenic prostate epithelial cell line, RWPE-1 (Figure 3.3B). Further work was 
performed, to assess the effect of inhibition or overexpression of miR-1207-3p on FN1 expression 
in RWPE-1 cells. qRT-PCR analysis showed that overexpression of miR-1207-3p induced nearly 
a 30% reduction of endogenous FN1 mRNA expression in RWPE-1 cells, while the inhibition of 
miR-1207-3p led to nearly a 4-fold increase in endogenous FN1 mRNA expression (Figure 3.3C). 
In addition, western blotting confirmed that overexpression of miR-1207-3p can significantly 
inhibit the protein level of FN1, with up to a 40% decrease in FN1 protein expression in three 
different PCa cell lines examined (Figure 3.3D). These findings demonstrate that FN1 is a 




Figure 3.3: miR-1207-3p regulates FN1 expression. (A & B) Two separate qRT-PCR and western 
blotting experiments were performed. Each qRT-PCR experiment was performed in quadruplicates. (C) 
Effect of overexpression and inhibition of miR-1207-3p on fibronectin expression in RWPE-1 cells. qRT-
PCR experiments were performed in quadruplicates, and three separate times. Statistical differences for A 
& C were determined with one-way ANOVA. All the criterions for significance was set at P<0.05.  (D) 
Effect of overexpression of miR-1207-3p on fibronectin expression in PC-3, E006AA cells, and E006AA-
hT cells. Western blot experiments were performed two separate times. (Originally published in 
Experimental Cell Research1). 
 
FNDC1 regulates proliferation, apoptosis, and migration of PCa cells 
To determine if miR-1207-3p effects on PCa cellular function are due to its inhibitory effect on 
FNDC1 expression, a FNDC1 small-interfering RNA (siRNA) was designed and used to determine 
if the effects of loss of FNDC1 expression are identical to the effects of overexpression of miR-
1207-3p on PCa cellular function. A dose-response experiment using MDA PCa 2b cells was 
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performed to determine the efficacy of our custom-designed FNDC1 siRNA in silencing FNDC1 
protein expression (Figure 3.4A). FNDC1 siRNA downregulated the expression of FNDC1 protein 
expression in MDA PCa 2b cells after 24-hour transfection best at 100pM concentration. This 
100pM concentration was used to determine the effect of silencing FNDC1 expression on 
apoptosis, proliferation and migration of PCa cells. To investigate whether FNDC1 regulates 
apoptosis, an Annexin V analysis was performed. Transient transfection with FNDC1 siRNA 
induced nearly 2-fold increase in apoptosis when compared to the scramble siRNA in C4-2B cells 
(Figure 3.4B). The EdU proliferation assay revealed that proliferation of MDA PCa 2b cells was 
inhibited by approximately 80% when compared to the scramble siRNA (Figure 3.4C).  We 
observed that migration, assessed via wound healing, of C4-2B cells was reduced significantly by 
approximately 55% by transfection with FNDC1 siRNA as compared to the scramble siRNA 
(Figure 3.4D). These results demonstrate that knockdown of FNDC1 via siRNA suppresses 
cellular proliferation and migration while inducing apoptosis in a manner similar to that observed 
for overexpression of miR-1207-3p, thus indicating that the cellular effects of miR-1207-3p are 




Figure 3.4: Effect of siRNA knockdown of FNDC1. (A) A dose response test of the effect of siRNA 
knockdown of FNDC1 was performed on MDA-PCa 2b using western blotting. Cells were treated with a 
non-targeting scramble siRNA and increasing concentrations of siRNA against FNDC1. Inhibition of 
FNDC1 expression by the FNDC1 siRNA was dose-dependent. (B) Effect of 100pM siRNA against 
FNDC1 on apoptosis of C4-2B cells via Annexin V staining. Inhibition of FNDC1 expression by the siRNA 
increases apoptosis. (C) Effect of 100pM siRNA against FNDC1 on proliferation in MDA PCa 2b cells 
using the Click-iT Edu proliferation assay (10X magnification). Inhibition of FNDC1 expression by the 
siRNA inhibits proliferation.  (D) Effect of 100pM siRNA against FNDC1 on C4-2b cells. Inhibition of 
FNDC1 expression by the siRNA inhibits migration. (Originally published in Experimental Cell 





FN1 regulates proliferation, apoptosis and migration of PCa cells 
Next, a dose-response experiment was used to determine the efficacy of the custom-designed FN1 
siRNA and appropriate concentrations for silencing FN1 protein expression (Figure 3.5A). We 
observed that FN1 protein expression in PC-3 cells were reduced most effectively at a 
concentration of 25pM, with an inhibition by approximately 80%. Therefore, this concentration 
was chosen to determine if the knockdown of FN1 using siRNA affects cell proliferation, 
migration and apoptosis in PCa cells in a manner similar to the effect of overexpression of miR-
1207-3p. FN1 protein expression decreased by up to 50% after transfection with FN1 siRNA 
compared to the scramble negative control siRNA in three different PCa cell lines tested (Figure 
3.5B). 
 
A direct analysis of cell proliferation was performed using EdU labeling on MDA PCa 2b cells. 
After 24 hours of transfection with either a scramble siRNA or 25pM FN1 siRNA, treatment with 
FN1 siRNA significantly inhibited cell proliferation by about 70% (Figure 3.5C). An analysis of 
the effects of FN1 siRNA on apoptosis using PC-3 cells was done by Annexin V analysis. We 
observed about 50% increase in apoptosis after FN1 silencing (Figure 3.5D). To assess the effect 
on cell migration, wound healing assays were performed using WPE1-NA22 cells. Inhibition of 
FN1 expression using the 25pm siRNA significantly inhibited migration by about 80% in WPE1-
NA22 compared to the scramble (Figure 3.5E). These results indicate that FN1 regulates apoptosis, 
proliferation and migration of PCa cells. The silencing of FN1 induced apoptosis, and inhibited 





Figure 3.5: Effect of siRNA knockdown of fibronectin. (A) A dose response test of the effect of siRNA 
knockdown of fibronectin was performed on PC-3 cells using western blotting. Cells were transfected with 
10pM non-targeting scramble siRNA and increasing concentrations of siRNA against fibronectin. 
Inhibition of fibronectin expression by our fibronectin siRNA was dose-dependent. (B) Effect of 25pM 
siRNA against fibronectin in PC-3 cells, E006AA cells, and E006AA-hT cells, respectively. Western blot 
experiments were performed three separate times. (C) Effect of a 25pM siRNA against fibronectin on 
proliferation in MDA PCa 2b cells was assessed using the Click-iT Edu proliferation assay (10X 
magnification). Inhibition of fibronectin expression by the fibronectin siRNA inhibits proliferation.  (D) 
Effect of 25pM siRNA against fibronectin on PC-3. Inhibition of fibronectin expression by the fibronectin 
siRNA increases apoptosis. (E) Effect of 25pM siRNA against fibronectin on WPE1-NA22. Inhibition of 
fibronectin expression by the fibronectin siRNA inhibits migration. (Originally published in Experimental 




miR-1207-3p regulates the androgen receptor via FNDC1/FN1 
It is well established that aberrant AR expression and activity play a critical role in the development 
and progression of PCa21,102-104.  Thus, we wanted to investigate if miR-1207-3p regulates AR in 
our novel pathway as this may play a determinant role in the progression from androgen-dependent 
PCa to the incurable androgen-independent PCa (CRPC). We initially assessed AR protein 
expression in the non-tumorigenic prostate epithelial cell line and PCa cell lines using western 
blotting. We observed that AR protein expression, similar to FNDC1 and FN1 protein expression, 
is overexpressed in the PCa cell lines compared to the non-tumorigenic prostate epithelial cell line, 
RWPE-1. Moreover, AR protein expression, similar to FNDC1 and FN1 protein expression, is 
very low in RWPE-1 (Figure 3.6A). In addition, FNDC1, FN1 and AR protein are overexpressed 
in the androgen-independent C4-2B PCa cell line compared to the androgen-dependent LNCaP 
PCa cell line (Figure 3.6B). Thus, the result shows that FNDC1 and FN1 expression positively 
correlate to AR expression in PCa cell lines. It is interesting to note that AR expression is 
negatively correlated with miR-1207-3p expression in PCa cell lines but is independent of the 
aggressiveness of the PCa cell line (Figure 3.1B). To determine if miR-1207-3p regulation of 
FNDC1/FN1 regulates AR expression, we examined the effect of silencing FNDC1 or FN1 
expression on AR expression in PCa. FN1 siRNA was transfected into MDA PCa 2b cells and we 
observed that compared to the scramble siRNA, FN1 siRNA inhibits AR expression (Figure 3.6C). 
Therefore, AR expression is dependent on FN1 expression.  
 
As we have already confirmed that miR-1207-3p directly targets the 3’UTR of FNDC1 leading to 
loss of its expression, we wanted to determine if loss of FNDC1 expression leads to the loss of 
FN1 and subsequent AR expression. Therefore, FNDC1 siRNA was transfected into MDA PCa 
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2b cells. To further clarify the role of miR-1207-3p in regulating FNDC1, and downstream 
molecular mechanisms, we also compared the effect of overexpression of miR-1207-3p to the 
effect of a negative control oligonucleotide. The western blot result clearly shows that the 
overexpression of miR-1207-3p inhibits the protein expression of FNDC1 (>60%), FN1 (~40%), 
and AR expression (~20%) (Figure 3.6D). The result positively correlates to that of the effect of 
silencing FNDC1, with protein expression inhibition of >70% for FNDC1, >50% for FN1. 
Remarkably, AR exhibits the most striking inhibition at nearly 85% (Figure 3.6D). Taken together, 
the results indicate that miR-1207-3p binds to the 3’UTR of FNDC1 leading to loss of expression 
of FNDC1, consequent loss of expression of FN1, and consequent loss of expression of AR. Thus, 
we have demonstrated, for the first time a miR-1207-3p/FNDC1/FN1/AR novel regulatory 
pathway.  
 
Figure 3.6: miR-1207-3p/FNDC1/FN1/AR is a regulatory pathway in prostate cancer. (A) AR is 
overexpressed in PCa cell lines when compared to the non-tumorigenic prostate epithelial cell line, RWPE-
1. (B) Relative protein expression of FNDC1, Fibronectin, and AR expression in LNCaP and C4-2b cells, 
respectively. (C) Effect of silencing fibronectin expression on AR expression in MDA PCa 2b cells. (D) 
Effect of overexpression of miR-1207-3p and silencing of FNDC1 on FNDC1, FN1 and AR expression in 
MDA PCa 2b cells. Western blotting experiments were performed three separate times. (Originally 
published in Experimental Cell Research1). 
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FNDC1, FN1, and AR expression are positively correlated in human prostate cancers and 
upregulation is associated with aggressive disease 
In view of this novel discovery of FNDC1, FN1 and AR as downstream molecular mechanisms of 
action of miR-1207-3p in PCa, we wanted to determine if they are relevant to clinically significant 
disease in human PCa patients. We independently analyzed data from three separate studies: 
Moffitt Cancer Center-based study, and analysis of two publicly available gene expression datasets 
in the Oncomine database (www.oncomine.org).  
 
In an independent study based at the Moffitt Cancer Center, we discovered that FN1 expression in 
PCa cases that resulted in overall death (3.01±1.92 versus 2.18±1.67, P=0.001) or PCa-specific 
death (2.88±2.11 versus 2.18±1.68, P=0.001) is significantly higher than PCa patients that 





Table 3.1. Fibronectin expression in prostate cancer tissues of 377 patients. List and characteristics of 
human prostate cancer samples. Variables: number, mean; SD, standard deviation; P-value. (Originally 
published in Experimental Cell Research1). 
 
Further, we independently investigated two additional publicly available gene expression datasets 
in the Oncomine database (www.oncomine.org) for expression of FNDC1, FN1, and AR.  Analysis 
of the study conducted by Lapointe et al 96 revealed similar levels of upregulation of all three genes 
in localized prostate cancers as compared to benign prostate tissues (FNDC1: 1.17 fold, p=0.002; 
FN1: 1.15 fold, p=0.005; AR: 1.12 fold, p=0.117) (Figure 3.7A).  Furthermore, metastatic prostatic 
cancers showed an even higher level of upregulation as compared to the localized prostate cancers 
(FNDC1: 1.80 fold, p=5.96e-4; FN1: 2.65 fold, p=0.063; AR: 2.87 fold, p=0.001) (Figure 3.7B).  
Similarly, in the dataset from the study by Grasso et al. 105, metastatic prostate cancers showed a 
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significant upregulation of all three genes when compared to localized primary prostate cancers 
(FNDC1: 3.87 fold, p=6.49e-9; FN1: 3.36 fold, p=1.01e-7; AR: 3.34 fold, p=6.27e-4) (Figure 3.7C).  
Together, these findings indicate a positive correlation between FNDC1, FN1, and AR expression 
in prostate cancers similar to that seen in prostate cancer cell lines, and their upregulation in 
metastatic prostate cancers supports a role for FNDC1, FN1, and AR in aggressive prostate 
cancers. 
 
Figure 3.7: FNDC1, FN1, and AR expression is correlated in prostate cancers and upregulation is 
associated with aggressive disease. (A) Expression of FNDC1, FN1 and AR genes in benign prostate 
tissues compared to localized prostate cancer. (B) Expression of FNDC1, FN1 and AR genes in localized 
prostate cancer compared to metastatic prostate cancer.  (C) Expression of FNDC1, FN1 and AR genes in 
localized primary prostate cancer compared to metastatic prostate cancer.  Results demonstrate upregulation 
of FNDC1, fibronectin and AR in aggressive disease. (Originally published in Experimental Cell 
Research1). 
 
miR-1207-3p is differentially expressed in PCa in men of African ancestry compared to 
Caucasian men 
For reasons still unclear, men of African ancestry (moAA) have the highest incidence of PCa 
globally 47,81-83. MoAA have approximately two-thirds higher incidence and two times the 
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increased mortality rate compared to Caucasian men (CM) 47,83,85,106. Additionally, moAA are 
more frequently diagnosed with worse clinicopathological features (PSA levels, Gleason grades, 
advanced tumor stage, etc.) than CM 81,83,88,107.  
 
Consequently, we investigated the clinical significance of miR-1207-3p in PCa and to determine 
if it contributes to the disproportionate aggressiveness of PCa in moAA. We observed that miR-
1207-3p expression was significantly less in PCa tissues of moAA in comparison to the PCa tissues 
of CM (3.00±2.65 versus 5.36±3.76, P = 0.016) (Table 3.2)2. This suggests that miR-1207-3p may 
play a role in explaining the disproportionately increased aggressiveness of PCa in moAA2.   
Variables N Mean ±SD P 
Race moAA 15 3.00±2.65  
CM 389 5.36±3.76 0.016 
Table 3.2: miR-1207-3p is differentially expressed between moAA and CM. Description and 
characteristics of human prostate cancer samples from 404 patients. N, Number; Avg, Average; SD, 
Standard Deviation; P, P-value. (Originally published in Translational Oncology2). 
 
miR-1207-3p regulates migration, apoptosis and proliferation of PCa cells 
To investigate the function of miR-1207-3p in prostate epithelial cells, we first evaluated its role 
in cell migration. Wound healing assays were performed using RWPE-1 (Figure 3.8A), WPE1-
NA22 (Figure 3.8B) and PC-3 cells (Figure 3.8C). As shown in figure 3.8A-C, inhibition of miR-
1207-3p expression with the miR-1207-3p inhibitor led to a four-fold increase in the migratory 
capacity of all three prostate epithelial cell lines. Conversely, overexpression of miR-1207-3p 
using the mimic of miR-1207-3p inhibited migration by 50% in both PCa cell lines, WPE1-NA22 





To investigate whether miR-1207-3p affects cell apoptosis, we performed Annexin V staining 
using flow cytometry on RWPE-1, MDA PCa 2b and C4-2B cells. We observed that for the normal 
prostate epithelial cell line, RWPE-1, the overexpression of miR-1207-3p mimic only slightly 
increased apoptotic activity. However, the miR-1207-3p inhibitor decreased apoptosis by nearly 
2-fold (Figure 3.8D). miR-1207-3p inhibitor decreased apoptosis, but overexpression of the miR-
1207-3p mimic resulted in increased apoptotic activity when compared to the negative control in 
MDA PCa 2b cells (Figure 3.8E). Similarly, the overexpression of miR-1207-3p mimic resulted 
in increased apoptosis in C4-2B cells, by nearly 2-fold, when compared to the negative control 
(Figure 3.8F). These results indicate that miR-1207-3p induces apoptosis in PCa cells. 
 
We next investigated whether miR-1207-3p regulates proliferation, by performing Click-iT EdU 
Alexa Flour 488 imaging assay. This sensitive method measures a cell’s ability to proliferate by 
assessing the cells in S-phase. As shown in figure 3.8G-I, the effect of miR-1207-3p mimic and 
the miR-1207-3p inhibitor were compared to the negative control in RWPE-1, MDA PCa 2b and 
WPE1-NA22 cells. For the normal prostate epithelial cell line, RWPE-1, we observed that 
overexpression of miR-1207-3p reduced EdU positive cells by approximately 30% compared to 
the negative control, while the inhibition of miR-1207-3p led to a nearly 2.5-fold increase in 
proliferation (Figure 3.8G). For MDA PCa 2b and WPE1-NA22 PCa cell lines, we observed that 
EdU positive cells were reduced by nearly 70% by the overexpression of miR-1207-3p compared 
to the negative control, while the inhibition of miR-1207-3p led to an approximate 40% increase 
in proliferation (Figure 3.8H & I). The diminished percentage of cells in S-phase caused by the 
overexpression of miR-1207-3p indicates that cells with overexpression of miR-1207-3p suspend 
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the cell cycle as they are unsuccessful to progress through the S-phase. The results demonstrate 
that increased expression of miR-1207-3p significantly inhibits cellular proliferation in PCa. 
 
Figure 3.8: Loss of miR-1207-3p expression promotes migration, proliferation and inhibits apoptosis. 
Transfection of a synthetic oligonucleotide mimic or inhibitor of miR-1207-3p was performed. (A) Effect 
of inhibition of miR-1207-3p expression on migration of RWPE-1 cells. (B & C) Effect of overexpression 
of miR-1207-3p and inhibition of miR-1207-3p on migration of WPE1-NA22 and PC-3 cells, respectively. 
Data indicate that loss of miR-1207-3p promotes migration. (D) Effect of overexpression of miR-1207-3p 
and inhibition of miR-1207-3p expression on apoptosis of RWPE-1 and MDA PCa 2b was assessed using 
Annexin V staining, respectively (D & E). Effect of overexpression of miR-1207-3p on apoptosis of C4-2b 
cells assessed using Annexin V staining.  Data indicate that overexpression of miR-1207-3p expression 
induces apoptosis (F). Effect of overexpression of miR-1207-3p and inhibition of miR-1207-3p expression 
on proliferation of RWPE-1, MDA PCa 2b and WPE1-NA22 cells assessed using the Click-iT EdU 
proliferation assay (10X magnification) (G-I). Results indicate that loss of miR-1207-3p increases 
proliferation.  Data is presented as mean + standard error of the mean (SEM). Statistical differences were 
determined with two-way ANOVA for B-C, G-I. All the criterions for significance was set at P<0.05. 




Prostate cancer (PCa) is the most frequently diagnosed solid organ cancer in males in the 
developed world 108.  Despite the high prevalence, the molecular mechanisms underlying its 
development and progression remain largely unclear. Increasing evidence has demonstrated that 
many miRNAs are aberrantly expressed in cancers, suggesting that variations in miRNA 
expression are common events in tumorigenesis34,41,43. These small non-coding RNAs are 
attractive for clinical applications for many reasons. One compelling reason is that miRNAs direct 
targeting of many mRNAs that are translated to proteins explains miRNAs differential expression 
between non-cancer and cancer cells. Understanding the regulatory pathways controlled by 
miRNAs is crucial as they can have significant impact on the regulation of various genes. The 
current study provides novel insight into the underlying molecular mechanisms for a potential 
tumor suppressive role for miR-1207-3p in PCa. The data suggest that it may be possible to exploit 
miR-1207-3p as a definitive therapeutic strategy in PCa.  
 
miRNA-1207-3p is encoded at the non-protein coding gene locus PVT1 on the 8q24 human 
chromosomal region, an established PCa susceptibility locus50,51. However, miRNA-1207-3p is 
not associated with any annotated PVT1 exons and no known functions have previously been 
described for miR-1207-3p. Thus, the function of miR-1207-3p may be different from that of 
PVT1 or any of its annotated exons. As the expression of miR-1207-3p in PCa has not previously 
been reported, our study is the first to demonstrate that miR-1207-3p regulates molecular 
mechanisms and central cellular functions associated with PCa development and progression. An 
important discovery is that miR-1207-3p is significantly underexpressed in human PCa cell lines 
as compared to normal prostate epithelial cells (by more than two-fold). Furthermore, based on the 
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observation that miR-1207-3p expression was further reduced in PCa cell lines derived from 
castration-resistant PCa (CRPC) versus castration-sensitive PCa, this study suggests that loss of 
miR-1207-3p may potentially be an early PCa biomarker of progression to CRPC. 
 
It is well known that being of African ancestry is a non-modifiable risk factor for PCa.82,83 These 
men are more than twice as likely to be diagnosed with PCa and more likely to have aggressive 
subtypes which increases their risk of mortality.83,109  Although the importance of miRNAs in PCa 
in moAA is still unclear, our results show that miR-1207-3p expression is particularly low in PCa 
cell lines derived from moAA (MDA PCa 2b, E006AA and E006AA-hT).  More importantly, 
results from human studies suggests that miR-1207-3p may contribute to the disproportionate 
aggressiveness of PCa in moAA. In this regard, miR-1207-3p is differentially expressed in primary 
tumors of moAA tissues compared to primary tumors of CM. To our knowledge, this is the first 
report of a microRNA that directly correlates with aggressive PCa, yet shows divergent expression 
between CM and moAA2. These data suggest that it may be possible to predict clinical behavior 
of PCa based upon miRNA-1207-3p expression in primary PCa.  While the overall sample size of 
the present study is relatively large, a limitation is the small sample size of the moAA sub-group. 
Although challenging, due to issues related to recruitment, a larger study enriched with a 
substantial proportion of moAA is warranted. In addition, the present study did not examine miR-
1207-3p expression in non-tumor versus tumor tissues. Therefore, the current data do not provide 
information regarding whether miR-1207-3p is differentially expressed in normal prostate versus 





Since the seven tumorigenic PCa cell lines studied showed consistent and significant 
underexpression of miR-1207-3p compared to the non-tumorigenic prostate epithelial cell line 
RWPE-1, we investigated the role of miR-1207-3p in regulating key cellular processes 
(proliferation, apoptosis, and migration) that are dysregulated during the development and 
progression of PCa. Whereas inhibition of miR-1207-3p expression leads to inhibition of apoptosis 
and increases in cellular proliferation of PCa cells, overexpression of miR-1207-3p significantly 
induced apoptosis and inhibited proliferation of PCa cells. Strikingly, inhibition of miR-1207-3p 
led to an approximately four-fold increase in the migratory capacity of both non-tumorigenic and 
tumorigenic prostate epithelial cells. These data demonstrate that miR-1207-3p regulates key 
cellular processes dysregulated in the development and progression of PCa110. Consequently, it is 
possible that miR-1207-3p could be applied to modulate these processes for therapeutic effects in 
PCa. Therefore, strategies to increase expression of miR-1207-3p in prostate epithelial cells 
deserve thorough investigation.  
 
The effect of miR-1207-3p on cellular migration is especially remarkable. Two miRNA molecular 
target algorithm tools, miRBase and miRDB, independently identify FNDC1 as a putative 
molecular target of miR-1207-3p.  As demonstrated, overexpression of miR-1207-3p inhibited 
expression of FNDC1 in multiple PCa cell lines. In addition, luciferase reporter assay and RNA 
pulldown assay confirmed that miR-1207-3p directly binds to FNDC1. Thus, we are first to 
demonstrate FNDC1 as a direct molecular target of miR-1207-3p. FNDC1 contains a major 
component of the structural domain of FN152,54,55,57,59. FN1 has been implicated in many cancers 
and known to be a major regulator of migration of cancer cells 61-64,111. Overexpression of miR-
1207-3p downregulates FN1, and specific silencing of FNDC1also downregulates FN1. Thus, 
miR-1207-3p effects in PCa are due to binding to and loss of FNDC1, and subsequent loss of FN1.  
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The biological function of FNDC1 has not been well studied. To our knowledge, this study is the 
first to demonstrate microRNA regulation of FNDC1. So far, only two miRNAs have been shown 
to directly target a member of the FN1 family in PCa, miRs-143 and-145 which are both 
downregulated in PCa cell lines and tissues65,66. However, these studies did not reach a consensus 
on their effects on FN134,65,67. Nevertheless, FN1 is upregulated in PCa as we observed from three 
independently analyzed human studies64,112. By identifying miR-1207-3p as a regulator of FN1, 
and its subsequent role in the regulation of proliferation, apoptosis, and migration, FNDC1 is 
shown to have a clear and prominent role in PCa. 
 
We have also demonstrated that miR-1207-3p regulates AR activity via FNDC1 and FN1. AR 
signaling is not only crucial for normal prostate growth and development but also for the onset and 
progression of prostate carcinogenesis104. Although AR signaling has been studied for decades, 
the molecular mechanisms behind its dysfunction remain unclear21,104,113. Undoubtedly, AR 
dysfunction precedes the progression CRPC21,103. We demonstrated that AR protein expression, in 
positive correlation with FN1 and FNDC1 protein expression, is significantly more elevated in the 
CRPC cellular model, C4-2B, in comparison to its castration-responsive counterpart, LNCaP. In 
summary, we have demonstrated the molecular effects of miR-1207-3p: loss of FNDC1 expression 
and consequent loss of FN1 expression lead to loss of AR expression. Thus, this is the first 




Figure 3.9: A novel miR-1207-3p/FNDC1/FN1/AR regulatory pathway in prostate cancer.  
 MicroRNA-1207-3p inhibits proliferation and migration and induces apoptosis of prostate cancer cells by 
the direct molecular targeting of the 3’UTR of FNDC1. miR-1207-3p induced loss of FNDC1expression 
leads to the sequential loss of FN1 and AR expression. (Originally published in RNA & Disease93). 
 
The clinical relevance of this novel regulatory pathway was investigated in several independently 
analyzed human prostate studies: Moffitt Cancer Center-based study, and analysis of two publicly 
available gene expression datasets in the Oncomine database (www.oncomine.org). To our 
knowledge, these are the first concurrent analyses of FNDC1, FN1, and AR in human PCa. Our 
Moffit Cancer Center-based study strongly showed that FN1 overexpression positively correlated 
with overall death and PCa-specific death in PCa. To our knowledge, this is the first description 
of FN1 as a prognostic biomarker in human clinical PCa. Importantly, analysis of the two publicly 
available gene expression datasets in the Oncomine database very strongly showed concurrent 
overexpression of FNDC1, FN1, and AR in metastatic PCa in comparison to primary tumors in 
both datasets. This is very clear evidence of an important role of this novel FNDC1/FN1/AR 
molecular pathway regulated by miR-1207-3p in the most clinically significant PCa, metastatic 
PCa. This underscores the importance of further studying miR-1207-3p for potential therapeutic 
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c-MYC is regulated and therapeutically targetable via the miR-1207-3p/FNDC1/FN1/AR 



















Although PCa is second leading cause of cancer-related death for men in the US, men with PCa 
do not die from localized prostate cancer9,12,11,25,103,105. Consequently, the major scientific 
challenge lies in understanding the molecular mechanisms by which prostate cancer progresses 
from the castration-responsive subtype to the lethal castration-resistant PCa (CRPC)17,25,103.  
 
In the US, the average 5-year survival rate for localized PCa is 100%, but for CRPC it is less than 
30%17,18,114. CRPC is resistant to androgen deprivation therapies (ADT), and is currently 
incurable17,18,25,103. Despite CRPCs resistance to ADT, it is now well established that a central 
mechanism driving CRPC progression is sustained androgen receptor (AR) signaling despite 
castration levels of testosterone which can be attributed to variable combinations of AR specific 
gene-amplification, mutations, increased AR sensitivity, and AR gene rearrangement promoting 
synthesis of constitutively-active truncated AR splice variants32,115-118.  Given the failure of ADT 
to completely abrogate AR-mediated functions in CRPC patients, there remains a significant 
demand for novel, effective and safe therapeutic strategies for CRPC115,118. Furthermore, the 
current tool for screening for PCa, prostate specific antigen (PSA), is highly controversial as it is 
not PCa-specific and has a high false positive rate14,15. Consequently, new biomarkers are urgently 
needed for the early detection of PCa, and it is crucial that these novel biomarkers are sensitive 
enough to discriminate between indolent PCa and CRPC.   
 
Because miRNAs are found to be dysregulated in many cancers, they have the potential to be used 
as potent tools to support the diagnosis and early detection of cancers7,27,43. Of note, miR-1207-3p 
is located downstream of the well-established proto-oncogene c-MYC on the 8q24 human 
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chromosomal region (Figure 4.1)72,97. c-MYC overexpression at the RNA and protein levels has 
subsequently been linked to a wide variety of human cancers72,75,76. Additionally, c-MYC is 
commonly found to be amplified in up to 72% of CRPCs72,75,76. Furthermore, significant 
amplification of c-MYC has been a consequence of antiandrogen treatment, and c-MYC is 
downstream of AR in some PCa75,76. Also, miRNAs have been implicated in the regulation of c-
MYC79,80,119. Nonetheless, the mechanisms regulating c-MYC remain unclear in PCa. 
 
 
Figure 4.1: c-MYC has been linked to prostate cancer aggressiveness. The chromosomal region 8q24 
is associated with aggressive PCa. miR-1207-3p is encoded at the PVT1 gene locus, which is located 
downstream of c-MYC. 
 
This study investigated if c-MYC is regulated by the novel miR-1207-3p/FNDC1/FN1/AR 
pathway in CRPC. We also describe for the first time miR-1207-3p’s ability to potentially improve 
risk stratification in human clinical PCa. Additionally, using in vitro CRPC cell models, the 
efficacy of NB1207 and NB5 was compared with second generation anti-androgen drugs to 






Underexpression of miR-1207-3p and the overexpression of FNDC1, FN1, AR and c-MYC 
are significantly associated with aggressive prostate cancer 
We assessed the expression profile of miRNA-1207-3p, FNDC1, FN1, AR and c-MYC in 
histologically confirmed normal prostate (n=24), benign prostatic hyperplasia tissue (n=44) and 
malignant prostate tumor tissue (n=29) from prostatectomy or transrectal ultrasound-guided 
biopsies in patients recruited at the University College Hospital, Ibadan, Nigeria, following an 
Institutional Ethics Board approved protocol. Analysis revealed that miR-1207-3p is significantly 
underexpressed in prostate tumor tissues (0.10±0.02, 95% CI [0.05, 0.149], P=0.000) in 
comparison to normal prostate tissue (1.02±0.17, 95% CI [0.67, 1.365], P=0.000) (Figure 4.2). 
Furthermore, there was significant differential miR-1207-3p expression in benign prostatic 
hyperplasia tissues (0.743±.15, 95% CI [.43, 1.05] P=0.004) in comparison to prostate tumor 
tissues (0.10±0.02, 95% CI [0.05, 0.149], P=0.004) (Figure 4.2). This is the first description of 
miR-1207-3p differential expression in human clinical PCa.  
 
Conversely, FNDC1 was significantly overexpressed in prostate tumor tissues (21.93±7.60, 95% 
CI [6.30, 37.54], p=0.006) in comparison to normal prostate tissues (1.62±0.41, 95% CI [0.756, 
2.48], p=0.006) (Figure 4.3A). Additionally, we discovered that FNDC1 was significantly 
overexpressed in prostate tumor tissues (21.93±7.60, 95% CI [6.30, 37.54], p=0.001) in 
comparison to benign prostatic hyperplasia tissues (1.22±.17, 95% CI [.86, 1.57] P=0.001) (Figure 
4.3A). We observed that similar positive correlation with advanced disease held true for FN1 
(tumor: 13.71 ± 3.31, 95% CI [6.93, 20.50], P=0.000; normal: 1.11 ± 0.22, 95% CI [0.66, 1.57], 
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P=0.000), (tumor: 13.71 ± 3.31, 95% CI [6.93, 20.50], P=0.000; benign prostatic hyperplasia 
tissues: 1.12 ± 0.20, 95% CI [0.72, 1.53], P=0.000),  AR (tumor: 20.33 ± 6.20, 95% CI [7.54, 
33.13], P=0.001; normal: 1.06 ± 0.22, 95% CI [0.61, 1.52], P=0.001), (tumor: 20.33 ± 6.20, 95% 
CI [7.54, 33.13], P=0.000; benign: 1.69 ± 0.23, 95% CI [1.21, 2.16], P=0.000) (Figure 4.3A-C),  
and c-MYC (tumor: 34.76 ± 8.11, 95% CI [18.09, 51.43], p=0.000; normal: 1.99 ± 0.34, 95% CI 
[1.27, 2.70]), (tumor: 34.76 ± 8.11, 95% CI [18.09, 51.43], p=0.000; benign: 1.01 ± 0.21, 95% CI 
[0.59, 1.43]), p=0.000) (Figure 4.4). The significantly increased mean expression for FNDC1, 
FN1, AR and c-MYC in prostate tumor tissues in comparison to normal prostate tissues 
demonstrate that their overexpression is associated with increased risk of cancer progression. Of 
note, this is the first description of miR-1207-3p serving as a candidate biomarker which can 




Figure 4.2: Underexpression of miR-1207-3p is significantly associated with aggressive PCa.  miR-
1207-3p, in histologically confirmed normal prostate (n=21), benign prostatic hyperplasia (n=41) and 
malignant prostate tissue (n=26) from prostatectomy or transrectal ultrasound-guided biopsies in patients 
recruited at the University College Hospital, Ibadan, Nigeria. Tissues were collected in compliance with 
Institutional Ethics Board approved protocols. All data were analyzed by the one-way ANOVA test & 





Figure 4.3. Overexpression of FNDC1, FN1, and AR are significantly associated with aggressive PCa. 
(A-C) FNDC1, FN1, and AR in histologically confirmed normal prostate, benign prostatic hyperplasia, and 
malignant prostate tissue from prostatectomy or transrectal ultrasound-guided biopsies in patients recruited 
at the University College Hospital, Ibadan, Nigeria. Tissues were collected in compliance with Institutional 
Ethics Board approved protocols. All data were analyzed by the one-way ANOVA test & Tukey post-hoc 





Figure 4.4: Overexpression of c-MYC is significantly associated with aggressive PCa.  c-MYC, in 
histologically confirmed normal prostate (n=21), benign prostatic hyperplasia (n=43) and malignant 
prostate tissue (n=27) from prostatectomy or transrectal ultrasound-guided biopsies in patients recruited at 
the University College Hospital, Ibadan, Nigeria. Tissues were collected in compliance with Institutional 
Ethics Board approved protocols. All data were analyzed by the one-way ANOVA test & Tukey post-hoc 
test. P < 0.05 were considered significant. 
 
miR-1207-3p negatively correlates with c-MYC in prostate tumors with Gleason score ≥8. 
Next, we wanted to access miR-1207-3p’s ability to improve risk stratification in human clinical 
PCa. We analyzed miR-1207-3p in histologically confirmed malignant prostate tumor tissues 
(n=23). We observed that miR-1207-3p was underexpressed by nearly 3-fold in patients with a 
Gleason score ≥8 (n=10) versus those with a Gleason score <8 (n=13) (Figure 4.5A). In contrast, 
we observed that c-MYC was overexpressed by nearly 5-fold in patients with a Gleason score ≥8 
(n=13) versus those with a Gleason score <8 (n=14) (Figure 4.5B). Therefore, miR-1207-3p 
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negatively correlates with c-MYC in tumors with Gleason score ≥8. This is the first description of 
miR-1207-3p’s potential role in risk stratification in human clinical PCa. 
 
Figure 4.5: miR-1207-3p negatively correlates with c-MYC in tumors with Gleason score ≥8. 
Expression profile of miR-1207-3p and c-MYC in histologically confirmed malignant prostate tissue 
(n=27) from prostatectomy or transrectal ultrasound-guided biopsies in patients recruited at the University 
College Hospital, Ibadan, Nigeria. Tissues were collected in compliance with Institutional Ethics Board 
approved protocols. All data were analyzed by the one-way ANOVA test & Tukey post-hoc test. P < 0.05 
were considered significant. 
 
c-MYC is downstream of the novel miR-1207-3p/FNDC1/FN1/AR pathway 
In light of our results demonstrating an inverse correlation between miR-1207-3p and c-MYC, we 
next investigated if c-MYC may possibly be a direct molecular target of miR-1207-3p. An RNA 
pulldown assay was performed using our custom-designed biotinylated miR-1207-3p duplex 
(NB1207) and our custom-designed biotinylated scramble oligonucleotide duplex (NB1), as a 
control. This technique allows for the definitive detection of miRNA-mRNA interactions1,93. C4-
55 
 
2B cells were transfected with either NB1207 or NB1, as a control. RNA pulled down was then 
analyzed for c-MYC expression with qRT-PCR. We observed that compared to the RNA pulled 
down by our custom-designed biotinylated scramble oligonucleotide sequence, the RNA pulled 
down by our custom-designed biotinylated miR-1207-3p duplex was not enriched for c-MYC 
expression (Figure 4.6A). Therefore, c-MYC is not a direct molecular target of miR-1207-3p. 
 
Although c-MYC is not a direct molecular target of miR-1207-3p, we observed an inverse 
association with miR-1207-3p and positive association with FNDC1, FN1 and AR in human PCa. 
Given that c-MYC has been reported to be downstream of AR in some PCa, we wanted to 
determine if c-MYC is downstream of the novel miR-1207-3p/FNDC1/FN1/AR pathway. 
Consequently, we assessed the effect of siRNAs against FNDC1, FN1 and AR on c-MYC mRNA 
and protein expression in the E006AA and the E006AA-hT PCa cell lines. Compared to the control 
scramble siRNA, siRNAs against FNDC1, FN1 and AR revealed significant suppression of c-
MYC expression by >90% in the E006AA PCa cell line and >75% in the E006AA-hT PCa cell 
line, validating that c-MYC is downstream of the novel miR-1207-3p/FNDC1/FN1/AR pathway 
and that miR-1207-3p regulates c-MYC expression via the miR-1207-3p/FNDC1/FN1/AR 




Figure 4.6: c-MYC is not a direct molecular target of miR-1207-3p but is regulated by the miR-1207-
3p/FNDC1/FN1/AR pathway. (A) Biotinylated miRNA pulldown was performed for the isolation of 
direct targets of a mature miRNA, using synthetic biotinylated miRNA duplexes. NB1 and NB1207 were 
transfected into C4-2B cells. Pull-down miRNA enrichments were assayed by RT-qPCR. (B-D) Effect of 
siRNAs against FNDC1, FN1 and AR on c-MYC mRNA expression in the indolent PCa cell line, E006AA, 
respectively. (E-G) Effect of siRNAs against FNDC1, FN1 and AR on c-MYC mRNA expression in the 
castration-resistant PCa cell line, E006AA-hT, respectively. Results are presented as mean + SEM. *P<0.05 




A novel synthetic analog of miR-1207-3p, NB1207, significantly inhibits c-MYC expression 
in CRPC cells. 
To further determine if miR-1207-3p regulates c-MYC, we assessed the effect of overexpression 
of miR-1207-3p on c-MYC protein expression, using NB1207, our synthetic analog of miR-1207-
3p. Using our panel of PCa cell lines, we discovered that c-MYC expression is higher in aggressive 
CRPC cell lines compared to non-aggressive CRPC and androgen-dependent PCa cell lines 
(Figure 4.7A). Of note, our results reveal that c-MYC expression is higher in the aggressive C4-
2B and E006AA-hT PCa cell lines when compared to their indolent counterparts, LNCaP and 
E006AA PCa cell lines, respectively (Figure 4.7A). This suggests that c-MYC is associated with 
aggressive PCa. 
 
To determine if NB1207 inhibits c-MYC expression, we explored the effect of overexpression of 
NB1207 on c-MYC mRNA and protein expression. We observed that NB1207 significantly 
inhibited c-MYC mRNA expression when compared with a control synthetic sequence in the 
CRPC cell lines, PC-3 (~60%), E006AA-hT (~35%) and C4-2B (~50%) (Figure 4.7B). Moreover, 
we observed that NB1207 significantly inhibited c-MYC protein expression when compared with 
the control synthetic sequence in the CRPC cell lines PC-3, E006AA-hT and C4-2B either as 
effectively or more effectively than the commercially available miR-1207-3p mimic (Sigma-
Aldrich MISSION® microRNA Mimic) (Figure 4.7C). We observed that in the CRPC cell lines, 
PC-3, E006AA-hT and C4-2B, miR-1207-3p regulates c-MYC expression via the miR-1207-
3p/FNDC1/FN1/AR pathway (Figure 4.7D-F). Compared to the controls (no transfection, control 
synthetic sequence, and scramble siRNA), c-MYC protein expression is inhibited in the CRPC cell 
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lines C4-2B (>75%), PC-3 (>80%) and E006AA-hT (>40%) by overexpression of miR-1207-3p, 
and loss of expression of FNDC1, FN1, and AR (Figure 4.7D-F). 
 
Figure 4.7: A novel miR-1207-3p/FNDC1/FN1/AR/c-MYC pathway in CRPC in which NB1207 
significantly inhibits c-MYC expression in CRPC cells. (A) Relative protein expression of c-MYC in 
PCa cell lines. (B) Effect of transfection of NB1207 on c-MYC mRNA expression in CRPC cell lines. (C) 
Comparison of effect of transfection NB1 or NB1207 on c-MYC protein expression compared to negative 
control or commercial miR-1207-3p mimic in CRPC cell lines. (D-F) Effect of novel miR-1207-
3p/FNDC1/FN1/AR/c-MYC pathway on c-MYC protein expression in CRPC cell lines. All results are 
presented as mean + standard error of the mean (SEM). *P<0.05 compared to the control. 
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NB1207 significantly inhibits migration, inhibits proliferation and induces apoptosis in 
CRPC cells. 
We next compared the effects of NB1207 to that of a commercially available miR-1207-3p mimic 
and scramble control on PCa cell proliferation, migration and apoptosis. We investigated whether 
NB1207 regulates migration similar to the miR-1207-3p mimic. Wound healing assays were 
performed to assess effect on migration of the E006AA-hT PCa cell line. We observed that 
migration of E006AA-hT cells was inhibited by nearly 50% by NB1207 compared to a scramble 
control sequence (NB1), whereas the commercially available miR-1207-3p mimic had no effect 
on E006AA-hT (Figure 4.8A). Using the MTT cell proliferation assay, we observed that 
proliferation of E006AA-hT CRPC cells was inhibited by nearly 40% by NB1207 compared to 
NB1, while the commercially available miR-1207-3p mimic had no effect on E006AA-hT (Figure 
4.8B). Therefore, the results demonstrate that NB1207 significantly inhibited cellular proliferation 
in CRPC. Lastly, using Annexin V assay to assess effect on apoptosis in E006AA-hT CRPC cells, 
we observed that apoptosis was increased by 2-fold in E006AA-hT cells by NB1207 compared to 
NB1, while the commercially available miR-1207-3p mimic had no effect (Figure 4.8C).  In 
conclusion, we discovered that NB1207 more effectively inhibited migration, inhibited 
proliferation and increased apoptosis in the CRPC cell line E006AA-hT PCa with increased c-
MYC expression when compared to the commercially available miR-1207-3p mimic. These data 




Figure 4.8: NB1207 significantly inhibits migration, inhibits proliferation and induces apoptosis in 
CRPC cells. Transfection of NB1 or NB1207 for 24 hours in the CRPC cell line E006AA-hT. (A) Wound 
healing assay was performed to assess effect on migration. (B) MTT assay was performed to assess effect 
on proliferation. (C) Annexin V assay was performed to assess effect on apoptosis. Results are presented 
as mean + standard error of the mean (SEM). *P<0.05 compared to the control. 
 
NB1207 and NB5 are more effective in inhibiting proliferation and inducing apoptosis in 
CRPC cells compared to enzalutamide, abiraterone and apalutamide. 
Based on consistent and highly reproducible data demonstrating underexpression of miR-1207-
3p in CRPC cells, we hypothesized that strategies to provide exogenous miR-1207-3p may have 
therapeutic effect in CRPC. Current anti-androgen therapies have concentrated on the androgen-
dependent activation of AR through its ligand-binding domain (LBD)20,115,118. However, recent 
studies have reported that AR-Vs which lack the LBD are resistant to these anti-androgen 
therapies.  Collectively, both ligand-dependent full-length AR (AR-FL) and AR-Vs regulate 
distinctive transcriptional strategies in CRPC20,115,118. Therefore, preventing/treating 
antiandrogen resistance is a major clinical challenge. It is already known that the detection of 
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AR-V7 in PCa CTCs has been correlated with CRPC and resistance against enzalutamide and 
abiraterone20,115,118. Consequently, we assessed the effects of miR-1207-3p on both the ligand-
induced activities of full-length AR and a constitutively active truncated AR lacking the LBD, 
AR-V7 in the CRPC cell line 22Rv1. To determine whether differences in AR-V7 protein levels 
was a result of miR-1207-3p expression and to compare the effect NB1207 and NB5 to 
abiraterone, enzalutamide and apalutamide, we examined protein levels of endogenous AR-V7 in 
the CRPC cell lines, C4-2B and 22Rv1. As indicated by Figure 4.7A, treatment of C4-2B and 
22Rv1 with NB1207 and NB5 dramatically reduced AR-V7 protein expression levels by more 
than 50% compared to the negative controls. Furthermore, in the aggressive CRPC cell line C4-
2B, NB1207 and NB5 more effectively inhibited AR-V7 compared to abiraterone, enzalutamide 
and apalutamide by ~40%, ~35% and ~25%, respectively (Figure 4.9A). Similarly, in 22Rv1, 
NB1207 and NB5 more effectively inhibited AR-V7 compared to abiraterone, enzalutamide and 
apalutamide by ~50%, ~60% and ~30%, respectively (Figure 4.9A).  Taken together, these 
results demonstrate the specific reduction of AR-V7 levels by synthetic analogs of miR-1207-3p 
is evident in CRPC models which express AR-V7. 
 
Next, we compared the efficacy of NB1207 and another novel synthetic miR-1207-3p analog 
(NB5, patent pending) with the efficacy of current anti-AR therapies abiraterone, enzalutamide 
and apalutamide on proliferation and apoptosis in CRPC cells which express both AR and AR-Vs. 
We first compared the efficacy in the androgen-sensitive LNCaP and E006AA PCa cell lines. 
Abiraterone, enzalutamide and apalutamide blocked cell proliferation as effectively as NB1207 
and NB5 in the non-CRPC LNCaP (~40%) and E006AA (~30%) PCa cell lines assessed by MTT 
assay (Figure 4.9B-C). Next, we again compared the effectiveness of NB1207 and NB5 to 
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enzalutamide, abiraterone and apalutamide on proliferation of the CRPC cell lines, C4-2B, 
E006AA-hT, PC-3 and 22Rv1 by MTT assay. We observed that in the CRPC cell lines, 
enzalutamide, abiraterone and apalutamide failed to significantly inhibit cell proliferation (Figure 
4.9D-G). However, both NB1207 and NB5 significantly inhibited the proliferative effect in C4-
2B (~50%), E006AA-hT (~50%), PC-3 (~40%), and in 22Rv1 (~50%) (Figure 4.9D-G).  
 
To confirm the observations observed by MTT assay in the CRPC cell lines, we performed the 
Click-iT EdU Alexa Flour 488 imaging assay. For the C4-2B and 22Rv1 CRPC cell lines, we 
observed that EdU positive cells were reduced by nearly 70% by both NB1207 and NB5 compared 
to the negative controls, while enzalutamide, abiraterone and apalutamide led to a 20%-30% 
decrease in proliferation (Figure 4.9H-I). As indicated in Figure 4.7H-I, NB1207 and NB5 
demonstrated more than 2-fold decrease in cellular proliferation in CRPC cells compared to 
enzalutamide, abiraterone and apalutamide. 
 
To examine whether NB1207 and NB5 overcomes the resistance to androgen antagonist therapy 
in CRPC cells in part by inducing cellular apoptosis, C4-2B and 22Rv1 cells were tested using 
Annexin V assay. We observed that NB1207 and NB5 increased apoptotic activity by more than 
7-fold in both CRPC cell lines when compared to the negative controls (Figure 4.10A-B). More 
importantly, NB 1207 and NB5 were >20% more effective in increasing apoptotic activity 
compared to enzalutamide, abiraterone and apalutamide in C4-2B cells (Figure 4.10A). NB1207 
and NB5 demonstrated even further superiority in 22Rv1 cells, as they demonstrated 
approximately 2-fold increase in apoptotic activity compared to enzalutamide, abiraterone and 
apalutamide (Figure 4.10B). Taken together, both NB1207 and NB5 inhibited proliferation and 
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increased apoptosis in CRPC cell lines which express both the androgen inducible AR-FL and the 




Figure 4.9. NB1207 and NB5 inhibits AR-V7 expression and is more effective in inhibiting 
proliferation in CRPC cells compared to abiraterone, enzalutamide, and apalutamide. (A) 
Comparison of effect of transfection NB1207 and NB5 on AR-V7 protein expression compared to 
negative controls or abiraterone, enzalutamide and apalutamide in CRPC cell lines.  MTT assay was 
performed to assess effect on cell viability. (B-G) Transfection of no transfection mix, DMSO, NB1, 
NB2, NB3, NB4, NB5, NB1207, enzalutamide, abiraterone or apalutamide for 24 hours in the non-
aggressive cell lines LNCaP and E006AA (B-C) and the CRPC cell lines C4-2B, E006AA-hT, PC-3 and 
22RV1 (D-G). EdU assay was performed to assess effect on cell proliferation. (H-I) Transfection of no 
transfection mix, DMSO, NB1, NB2, NB3, NB4, NB5, NB1207, enzalutamide, abiraterone or 




Figure 4.10. NB1207 and NB5 are more effective in inducing apoptosis in CRPC cells compared to 
enzalutamide, abiraterone and apalutamide. Annexin V assay was performed to assess effect on cell 
apoptosis. (A-B) Transfection of no transfection mix, DMSO, NB1, NB2, NB3, NB4, NB5, NB1207, 
enzalutamide, abiraterone or apalutamide for 24 hours in the CRPC cell lines C4-2B and 22Rv1. Results 






Men with advanced disease typically receive androgen deprivation therapy (ADT) with new 
second-generation therapeutic agents such as enzalutamide or abiraterone17,120. Yet, it is well 
established that these patients who receive ADT inescapably succumb to their relapsed tumor after 
a period where the disease is in remission11,17,103. As PCa is a heterogeneous disease, the chief 
obstacle is understanding the molecular mechanisms involved in this progression from the 
asymptomatic androgen-dependent PCa to the lethal CRPC. Consequently, new biomarkers and 
treatment strategies are urgently required to combat CRPC.  
 
This is the first report to show that miR-1207-3p regulates c-MYC expression via the miR-1207-
3p/FNDC1/FN1/AR pathway in aggressive PCa. c-MYC is a vital transcription factor and a crucial 
protein, and direct targeting may have severe consequences on patients72-75,79,121. Because c-MYC 
targeting has proved difficult, our data demonstrating the regulation of c-MYC expression by the 
miR-1207-3p/FNDC1/FN1/AR pathway bears significant implications for treatment of c-MYC-
driven cancers. Excitingly, targeting miR1207-3p may be less challenging and the effects may be 
less deleterious than targeting c-MYC itself for inhibiting c-MYC driven cancers72-75,79,121. Our 
findings have illuminated the molecular details of miR-1207-3p/c-MYC cooperation and the 
synthesis of the novel NB1207 and NB5 as candidate therapeutics specifically targeting the miR-
1207-3p/FNDC/FN1/AR/c-MYC pathway in CRPC. 
 
We have also demonstrated the potential diagnostic and prognostic value of miR-1207-3p in 
CRPC. Currently, the Gleason grading system represents an invasive technique which evaluates 
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the prognosis of men with PCa using samples from a prostate biopsy. From the perspective of 
personalized medicine, an improved strategy for better patient stratification and treatment response 
should include the monitoring of specific miRNAs5,25,34,122. Various studies have established the 
stability of miRNAs in serum, plasma and urine as well as the differential expression of miRNAs 
in normal and tumor tissue which demonstrates the potential of miRNAs as potential PCa 
biomarkers and predictors of therapy response2,5,7,43. Accordingly, our prostate tissue analysis 
revealed that underexpression of miR-1207-3p and the overexpression of FNDC1, FN1, AR and 
c-MYC are significantly associated with aggressive PCa. Furthermore, we observed that miR-
1207-3p, FNDC1, FN1, AR and c-MYC were significantly differentially expressed between 
benign prostatic hyperplasia and PCa.  Also, miR-1207-3p was underexpressed while c-MYC was 
overexpressed in tumors with Gleason score ≥8 in comparison to those with Gleason score <8. 
These findings demonstrate the potential usefulness of miR-1207-3p and c-MYC for PCa risk 
stratification.  
 
The observation of decreased miR-1207-3p expression during PCa progression indicates that 
strategies to enhance miR-1207-3p in PCa may have therapeutic value in CRPC. miRNAs can 
simultaneously modulate several cancer-relevant gene pathways and can be exploited to increase 
the sensitivity of tumor cells to conventional anticancer agents5,7,27,34,39,44,122,123. Because of this 
potential to be one-hit multi-target therapeutic agents against PCa, miRNAs are interesting 
therapeutic candidates27,34,123,124. We observed that the novel candidate therapeutic, NB1207, 
significantly inhibited c-MYC protein expression in the CRPC cell lines. Furthermore, NB1207 
significantly inhibited migration, inhibited proliferation and induced apoptosis in CRPC cell lines. 
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Therefore, these in vitro studies demonstrate the potential of miR-1207-3p analogs, such as 
NB1207 and NB5 serving as therapeutics for CRPC.  
 
Consequently, we investigated if NB1207 and NB5 could have efficacy against CRPC cells that 
have proven to be resistant to both first generation and second generation ADTs. The notion that 
those PCas continuing to progress during ADT are androgen independent has been reconsidered 
in the last few years and it is now accepted that AR signaling plays a significant role in CRPC 
despite castrate-levels of testosterone17,103,105,122. Important advances in the understanding of the 
mechanism involved in CRPC pathogenesis have led to welcome breakthrough of several AR-
targeting drugs such as abiraterone, enzalutamide and apalutamide17,125-129. However, despite their 
promising effects in some patients with CRPC, approximately 20-40% of patients do not benefit 
from these agents and eventually all the initial responders to these drugs acquire secondary drug 
resistance leading to death115,118. Recent studies have reported that AR-Vs signal in the absence of 
the ligand binding domain (LBD) which are a crucial contributing factor for resistance to LBD-
targeting AR antagonists or agents that repress androgen biosynthesis such as abiraterone, 
enzalutamide and apalutamide20,115,118. Among the variants, AR-V7 is the most studied member 
because it is the only known variant of which the encoded endogenous protein is detectable in 
clinical specimens20,28,115. Studies have shown a strong association between the presence and 
overexpression of AR-V7 in CRPC and resistance to the current drug regimen20,28,115,116. This 
resistance is a major clinical challenge in the field and a clearer understanding of the mechanisms 
underlying resistance to these drugs would facilitate selection of alternative novel therapeutic 
strategies20,28,115.  Consequently, we have demonstrated that NB1207 and NB5 significantly 
inhibited AR-V7 protein expression in the CRPC models, C4-2B and 22Rv1. 
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In that regard, the efficacy of our novel candidate therapeutics, NB1207 and NB5, against CRPC 
cells is of tremendous interest. We discovered that NB1207 and NB5 is as effective as abiraterone, 
enzalutamide and apalutamide in significantly preventing proliferation and increasing apoptotic 
activity in non-CRPC cell lines. Strikingly, our results demonstrate significant anti-proliferative 
and pro-apoptotic effects of NB5 and NB1207 in CRPC cell lines whereas abiraterone, 
enzalutamide and apalutamide were less effective. Our novel miR-1207-3p/FNDC1/FN1/AR/c-
MYC pathway suggests that the role of AR-V7 on CRPC development and PCa progression may 
be mediated in part via c-MYC. Moreover, NB5 and NB1207 may be promising therapeutic agents 
against AR-V7 expressed CRPC by serving as c-MYC inhibitors. Based on our data, it is likely 
this may be less susceptible than all current ADTs to the development of resistance in advanced 
PCa28,115.  
 
In conclusion, this is the first report to show the potential diagnostic and prognostic value of miR-
1207-3p as it has been shown to be a candidate biomarker for risk stratification. NB1207 and NB5 
are efficacious in inhibition of proliferation of CRPC and increasing the apoptotic activity of 
CRPC via targeting c-MYC. Overall, our results demonstrate a preclinical proof-of-principle that 
NB5 and NB1207, our novel analogs of miR-1207-3p, may be promising therapeutics for the 
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In Chapter 1 we presented the rationale for investigating the role of miR-1207-3p in PCa. 
Understanding the molecular mechanisms of PCa progression is essential for the discovery of 
robust prognostic markers which we believe are capable of helping to identify those patients that 
are at the greatest risk of relapse17,20,25. This will, in turn, enable us to optimize management 
strategies to control PCa progression. In that light, the importance of miRNAs in cancer biology 
has become apparent for the discovery of miRNA-based diagnostic, prognostic and theranostic 
biomarkers7,39,43,124. Moreover, their relative stability in tissues and a variety of biofluids including 
blood and urine makes repeated measurements of miRNA levels by qRT-PCR assays very 
feasible8,39,124,130,131. This can provide critical information on a disease’s molecular signature status 
over time through the course of treatment and recurrence without the need for a biopsy5,43.   
 
We made several novel findings. We discovered that expression of miR-1207-3p is significantly 
diminished in PCa cells1. We also demonstrated that increased expression of miR-1207-3p in PCa 
cells significantly inhibits migration and proliferation, and induces apoptosis via direct molecular 
targeting of FNDC11. These functional experiments clearly demonstrate a mechanism by which 
miR-1207-3p regulates key cellular processes dysregulated in the development and progression of 
PCa. Importantly, we describe for the first time the miR-1207-3p/FNDC1/FN1/AR novel 
regulatory pathway in PCa: miR-1207-3p-induced loss of FNDC1 expression leads to the loss of 
FN1 and subsequently AR expression1. Our novel pathway has important clinical implications as 
miRNAs possess several key features that make them attractive PCa biomarkers33,34,43. Our clinical 
results indicate that FNDC1, FN1, and AR are concurrently overexpressed in metastatic PCa1.  
Also, FN1 overexpression in prostate tumors positively correlated with overall death and PCa-
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specific death1. To our knowledge this is the first description of FN1 as a potential prognostic 
biomarker in human clinical PCa.   
 
To identify the target genes of miR-1207-3p in PCa and to investigate the involvement of miR-
1207-3p target genes in PCa, we designed and synthesized a novel synthetic biotinylated miR-
1207-3p duplex (NB1207) and scramble duplex (NB1) (Patent application publication number, 
US20170121711 A1). Prior to using the NB1207 for target discovery, we compared their effects 
to that of the previously used commercially available miR-1207-3p mimic on the 3’UTR of 
FNDC1, and PCa cell proliferation, migration and apoptosis. Of significance, we observed that 
NB1207 maybe be more efficient than the commercially available mimic as NB1207 significantly 
inhibited migration, inhibited proliferation and induced apoptosis in several CRPC cell lines while 
the mimic had little effect. We have already used these novel tools (NB1207 and NB1) to perform 
a RNA pull down assay that demonstrated that FNDC1 is a direct molecular target of miR-1207-
3p. This gives us the confidence and the ability to identify all the molecular targets of miR-1207-
3p. Future work will employ these tools in a RNA pulldown approach followed up with RNA 
sequencing of the enriched RNA pulled down to identify all directly bound RNA molecular targets 
of miR-1207-3p.  
 
As a sub-study, we investigated the impact of racial disparity in PCa because moAA have a 2-fold 
higher chance of getting aggressive PCa. Despite progress being made in the field, significant PCa 
racial disparity persists82,83,109.  In this regard, we discovered that miR-1207-3p is differentially 
expressed in primary tumors from moAA tissues compared to primary tumors of CM. To our 
knowledge, this is the first report of a microRNA that directly correlates with aggressive PCa and 
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has divergent expression between CM and moAA. The discovery of a miRNA biomarker that is 
capable of displaying differential expression in men of different ancestry is of great significance 
for the development and optimization of miR-1207-3p-based therapeutic strategies for 
personalized treatment approaches. Further studies are required to establish this.  
 
In Chapter 4, we investigated the relationship of miR-1207-3p with the proto-oncogene, c-MYC. 
Our results demonstrated that it may be possible to predict clinical behavior of PCa based upon 
miRNA-1207-3p expression. Approximately 30% of PCa patients develop clinical recurrence, and 
the survival period of this phase of PCa is limited and extremely variable, the challenge lies in the 
identification of those patients most at risk for relapse6,12,17,25. Because c-MYC is commonly found 
to be amplified in up to 72% of CRPCs, targeting c-MYC could be a potential approach against 
CRPC. Yet, the mechanisms regulating c-MYC have not been fully delineated in PCa.  
 
We discovered the underexpression of miR-1207-3p and the overexpression of FNDC1, FN1, AR 
and c-MYC is associated with increased risk of cancer progression and aggressive PCa. 
Investigations into miR-1207-3p ability to improve risk stratification in human clinical PCa by 
determining if there are any correlation with Gleason scores demonstrated that miR-1207-3p 
negatively correlates with c-MYC in tumors with Gleason score ≥8. This is of clinical significance 
for several reasons. Currently, factors such as serum PSA level, Gleason score, and tumor stage 
are used for diagnosis, prognostication and treatment decision-making8,132. However, none of these 
alone or in combination are adequate indicators for accurate clinical decision-making6,105,133. It is 
likely that heterogeneity of PCa at the molecular level may account for the fact that even those 
patients displaying similar PSA levels, tumor stage, Gleason score can still have different clinical 
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outcomes 6,105,133. Furthermore, factors to detect recurrence such as increased serum PSA levels 
may actually lead to false positive diagnosis124. Moreover, increased PSA following radical 
prostatectomy can be caused by the presence of residual benign prostate tissue14,15,134.  Considering 
these current limitations, our discovery adds to the “tool-box” to improve the clinical decision-
making process2. To our knowledge, this is the first study to evaluate the expression of miR-1207-
3p in any human disease and the first description of miR-1207-3p differential expression in human 
clinical PCa1. Importantly, this is the first report to show the potential diagnostic value of miR-
1207-3p as it has been shown to be a candidate biomarker for risk stratification in human clinical 
PCa. 
 
In Chapter 4, we also confirmed that c-MYC is not a direct molecular target of miR-1207-3p yet 
is regulated by our pathway. Consequently, we have discovered a novel miR-1207-
3p/FNDC1/FN1/AR/c-MYC pathway in PCa.  Additionally, using miR-1207-3p analogs (NB1207 
and NB5), we discovered that overexpression of miR-1207-3p more effectively inhibited 
proliferation and increased apoptosis in the CRPC cell lines. Our reproducible results had 
prompted us to envision miR-1207-3p as a therapeutic to help health care professionals combat 
CRPC in patients. Current anti-androgen therapies including enzalutamide, abiraterone and 
apalutamide are unable to inhibit proliferation and increase apoptosis in CRPC cell lines such as 
C4-2B. Thus the question which remained is can our novel miR-1207-3p analogs demonstrate 
efficacy in CRPC where current CRPC treatments have failed?  We observed that treatment with 
NB1207 and NB5 inhibited AR-V7 protein expression in CRPC cells and more significantly 
inhibited proliferation and increased apoptosis of CRPC cells compared to abiraterone, 
enzalutamide and apalutamide. These results demonstrate that use of synthetic analogs of miR-
75 
 
1207-3p such as NB5 and NB1207 may be a novel strategy for successful therapeutic targeting of 
c-MYC in CRPC.   
 
In summary, we present mechanistic and clinical data characterizing the novel miR-1207-
3p/FNDC1/FN1/AR/c-MYC molecular pathway suggesting its role in PCa (Figure 5.1)1. We 
conclude that the present study signifies that miR-1207-3p may have potential diagnostic, 
prognostic, and therapeutic applications in PCa. Furthermore, our results demonstrate proof-of-
principle that NB1207 and NB5 may be promising therapeutics for the treatment of CRPC.  
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